| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Brain Neoplasms | 416 | 2025 | 9213 | 23.980 |
Why?
|
| Glioma | 187 | 2025 | 3532 | 18.320 |
Why?
|
| Glioblastoma | 218 | 2025 | 3525 | 17.740 |
Why?
|
| Angiogenesis Inhibitors | 62 | 2023 | 2059 | 7.210 |
Why?
|
| Neoplasm Recurrence, Local | 120 | 2025 | 9442 | 5.890 |
Why?
|
| Meningeal Neoplasms | 50 | 2024 | 1258 | 5.720 |
Why?
|
| Central Nervous System Neoplasms | 34 | 2025 | 930 | 5.140 |
Why?
|
| Meningioma | 37 | 2024 | 1226 | 4.960 |
Why?
|
| Dacarbazine | 42 | 2022 | 559 | 4.850 |
Why?
|
| Antineoplastic Agents | 118 | 2024 | 13698 | 4.590 |
Why?
|
| Isocitrate Dehydrogenase | 31 | 2025 | 958 | 4.070 |
Why?
|
| Antineoplastic Agents, Alkylating | 27 | 2024 | 618 | 3.720 |
Why?
|
| Clinical Trials as Topic | 61 | 2025 | 8055 | 3.400 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 63 | 2024 | 11886 | 2.420 |
Why?
|
| Cranial Irradiation | 11 | 2020 | 395 | 2.070 |
Why?
|
| Brain Edema | 9 | 2021 | 607 | 2.000 |
Why?
|
| Oligodendroglioma | 14 | 2024 | 278 | 1.990 |
Why?
|
| Nervous System Neoplasms | 5 | 2015 | 91 | 1.870 |
Why?
|
| Pyridines | 17 | 2024 | 2895 | 1.840 |
Why?
|
| Humans | 638 | 2025 | 768970 | 1.830 |
Why?
|
| Astrocytoma | 20 | 2024 | 781 | 1.820 |
Why?
|
| Mutation | 62 | 2025 | 30266 | 1.740 |
Why?
|
| Quinazolines | 28 | 2017 | 1373 | 1.650 |
Why?
|
| Pyrimidines | 15 | 2024 | 3048 | 1.530 |
Why?
|
| Disease-Free Survival | 57 | 2021 | 6856 | 1.500 |
Why?
|
| Receptors, Vascular Endothelial Growth Factor | 16 | 2017 | 664 | 1.470 |
Why?
|
| Vascular Endothelial Growth Factor A | 20 | 2023 | 3518 | 1.440 |
Why?
|
| Imidazoles | 11 | 2024 | 1169 | 1.430 |
Why?
|
| Endpoint Determination | 12 | 2020 | 594 | 1.420 |
Why?
|
| Adult | 247 | 2025 | 223851 | 1.320 |
Why?
|
| Neurology | 7 | 2024 | 787 | 1.310 |
Why?
|
| Disease Progression | 49 | 2023 | 13674 | 1.300 |
Why?
|
| Somatostatin | 3 | 2015 | 458 | 1.270 |
Why?
|
| Combined Modality Therapy | 42 | 2025 | 8559 | 1.260 |
Why?
|
| Molecular Targeted Therapy | 18 | 2024 | 2830 | 1.210 |
Why?
|
| Treatment Outcome | 127 | 2025 | 65480 | 1.210 |
Why?
|
| Anilides | 5 | 2018 | 414 | 1.200 |
Why?
|
| Lomustine | 9 | 2023 | 60 | 1.180 |
Why?
|
| Medical Oncology | 16 | 2025 | 2350 | 1.180 |
Why?
|
| Enzyme Inhibitors | 13 | 2024 | 3726 | 1.170 |
Why?
|
| Anticonvulsants | 25 | 2024 | 1924 | 1.170 |
Why?
|
| Research Design | 23 | 2025 | 6214 | 1.170 |
Why?
|
| Oxazines | 2 | 2020 | 358 | 1.160 |
Why?
|
| Protein Kinase Inhibitors | 21 | 2023 | 5707 | 1.160 |
Why?
|
| Aged | 200 | 2025 | 171786 | 1.150 |
Why?
|
| Magnetic Resonance Imaging | 77 | 2024 | 36854 | 1.120 |
Why?
|
| Middle Aged | 225 | 2025 | 223737 | 1.100 |
Why?
|
| Adrenal Cortex Hormones | 9 | 2019 | 1892 | 1.090 |
Why?
|
| Salvage Therapy | 12 | 2018 | 1277 | 1.050 |
Why?
|
| Neovascularization, Pathologic | 17 | 2024 | 2634 | 1.030 |
Why?
|
| Seizures | 14 | 2024 | 3000 | 1.010 |
Why?
|
| Radiosurgery | 18 | 2023 | 1346 | 0.990 |
Why?
|
| Clinical Trials, Phase II as Topic | 11 | 2020 | 640 | 0.980 |
Why?
|
| Male | 261 | 2025 | 365203 | 0.950 |
Why?
|
| Prognosis | 79 | 2025 | 30046 | 0.950 |
Why?
|
| Antineoplastic Agents, Hormonal | 4 | 2015 | 1535 | 0.940 |
Why?
|
| Blood-Brain Barrier | 8 | 2024 | 1036 | 0.910 |
Why?
|
| Models, Neurological | 5 | 2010 | 1782 | 0.900 |
Why?
|
| Female | 250 | 2025 | 397515 | 0.890 |
Why?
|
| Survival Rate | 55 | 2025 | 12873 | 0.890 |
Why?
|
| Maximum Tolerated Dose | 19 | 2024 | 899 | 0.880 |
Why?
|
| Head | 5 | 2010 | 927 | 0.880 |
Why?
|
| Aminopyridines | 6 | 2020 | 580 | 0.870 |
Why?
|
| Radiotherapy | 14 | 2017 | 1506 | 0.860 |
Why?
|
| World Health Organization | 8 | 2022 | 1328 | 0.860 |
Why?
|
| Recombinant Fusion Proteins | 10 | 2020 | 3744 | 0.850 |
Why?
|
| Consensus | 16 | 2025 | 3214 | 0.850 |
Why?
|
| Clinical Trials, Phase I as Topic | 3 | 2015 | 330 | 0.850 |
Why?
|
| Proto-Oncogene Proteins B-raf | 10 | 2023 | 2059 | 0.820 |
Why?
|
| DNA Repair Enzymes | 12 | 2023 | 346 | 0.810 |
Why?
|
| Problem Solving | 2 | 2015 | 443 | 0.810 |
Why?
|
| DNA Modification Methylases | 11 | 2023 | 210 | 0.800 |
Why?
|
| Cancer Vaccines | 7 | 2024 | 1043 | 0.800 |
Why?
|
| Antibodies, Monoclonal | 21 | 2022 | 9264 | 0.790 |
Why?
|
| Tumor Burden | 14 | 2023 | 1913 | 0.790 |
Why?
|
| Gliosarcoma | 11 | 2022 | 115 | 0.790 |
Why?
|
| Hydroxamic Acids | 3 | 2015 | 483 | 0.780 |
Why?
|
| Neoadjuvant Therapy | 5 | 2024 | 2909 | 0.780 |
Why?
|
| Central Nervous System | 6 | 2023 | 1346 | 0.770 |
Why?
|
| Patient Selection | 7 | 2020 | 4265 | 0.760 |
Why?
|
| Diamines | 1 | 2021 | 60 | 0.740 |
Why?
|
| Pepsin A | 1 | 2021 | 64 | 0.730 |
Why?
|
| Indoles | 6 | 2015 | 1836 | 0.730 |
Why?
|
| Neoplasms | 24 | 2025 | 22389 | 0.720 |
Why?
|
| Morpholines | 4 | 2020 | 584 | 0.710 |
Why?
|
| Glycine | 3 | 2022 | 672 | 0.710 |
Why?
|
| Chemotherapy, Adjuvant | 11 | 2019 | 3554 | 0.710 |
Why?
|
| Diagnostic Imaging | 12 | 2022 | 3538 | 0.700 |
Why?
|
| Lactoferrin | 1 | 2021 | 100 | 0.700 |
Why?
|
| Neoplastic Cells, Circulating | 4 | 2022 | 957 | 0.700 |
Why?
|
| Positron-Emission Tomography | 12 | 2024 | 6673 | 0.690 |
Why?
|
| Fatigue | 6 | 2017 | 1557 | 0.690 |
Why?
|
| Phosphatidylinositol 3-Kinases | 9 | 2023 | 2884 | 0.690 |
Why?
|
| Drug Resistance, Neoplasm | 19 | 2024 | 5342 | 0.670 |
Why?
|
| Editorial Policies | 2 | 2015 | 460 | 0.660 |
Why?
|
| Pyridones | 7 | 2024 | 819 | 0.660 |
Why?
|
| Pharmaceutical Preparations | 4 | 2023 | 1088 | 0.650 |
Why?
|
| Phosphatidylinositol 3-Kinase | 2 | 2023 | 126 | 0.650 |
Why?
|
| Brain | 36 | 2022 | 27453 | 0.650 |
Why?
|
| Young Adult | 65 | 2025 | 60131 | 0.650 |
Why?
|
| Histones | 5 | 2024 | 2603 | 0.640 |
Why?
|
| Peripheral Nervous System Diseases | 8 | 2018 | 716 | 0.610 |
Why?
|
| Immunotherapy | 23 | 2024 | 4756 | 0.610 |
Why?
|
| Radiation Injuries | 8 | 2020 | 1203 | 0.610 |
Why?
|
| Ependymoma | 2 | 2021 | 328 | 0.610 |
Why?
|
| Sirolimus | 10 | 2014 | 1540 | 0.600 |
Why?
|
| Topoisomerase I Inhibitors | 1 | 2018 | 70 | 0.590 |
Why?
|
| Sural Nerve | 1 | 2018 | 105 | 0.590 |
Why?
|
| Survival Analysis | 33 | 2023 | 10115 | 0.580 |
Why?
|
| Dental Caries | 1 | 2021 | 429 | 0.580 |
Why?
|
| Pyridazines | 1 | 2019 | 203 | 0.580 |
Why?
|
| Angiopoietins | 1 | 2017 | 86 | 0.570 |
Why?
|
| Neurotoxicity Syndromes | 3 | 2012 | 302 | 0.560 |
Why?
|
| Epothilones | 2 | 2015 | 42 | 0.520 |
Why?
|
| TOR Serine-Threonine Kinases | 4 | 2020 | 2063 | 0.520 |
Why?
|
| Decision Making | 5 | 2023 | 3953 | 0.520 |
Why?
|
| Receptors, CXCR4 | 2 | 2018 | 729 | 0.520 |
Why?
|
| Piperidines | 4 | 2015 | 1667 | 0.520 |
Why?
|
| Practice Guidelines as Topic | 9 | 2021 | 7460 | 0.510 |
Why?
|
| Lung Neoplasms | 18 | 2023 | 13594 | 0.510 |
Why?
|
| Kaplan-Meier Estimate | 19 | 2019 | 6547 | 0.510 |
Why?
|
| Randomized Controlled Trials as Topic | 20 | 2025 | 10400 | 0.500 |
Why?
|
| Retrospective Studies | 71 | 2025 | 81903 | 0.490 |
Why?
|
| Follow-Up Studies | 51 | 2025 | 39394 | 0.490 |
Why?
|
| Venous Thrombosis | 3 | 2019 | 1321 | 0.490 |
Why?
|
| Diffusion Magnetic Resonance Imaging | 8 | 2020 | 2831 | 0.480 |
Why?
|
| Diagnosis, Computer-Assisted | 3 | 2010 | 709 | 0.480 |
Why?
|
| Aged, 80 and over | 54 | 2024 | 59739 | 0.480 |
Why?
|
| Epilepsy | 7 | 2024 | 3326 | 0.480 |
Why?
|
| Signal Transduction | 22 | 2019 | 23653 | 0.470 |
Why?
|
| Cerebellar Neoplasms | 5 | 2024 | 591 | 0.470 |
Why?
|
| Small Cell Lung Carcinoma | 1 | 2020 | 454 | 0.470 |
Why?
|
| Dose-Response Relationship, Drug | 24 | 2020 | 10765 | 0.470 |
Why?
|
| Electric Conductivity | 5 | 2010 | 408 | 0.470 |
Why?
|
| Pathology, Molecular | 3 | 2023 | 329 | 0.470 |
Why?
|
| Sick Role | 1 | 2015 | 229 | 0.470 |
Why?
|
| Tissue Distribution | 11 | 2020 | 2298 | 0.470 |
Why?
|
| Radiation-Sensitizing Agents | 4 | 2013 | 349 | 0.460 |
Why?
|
| DNA Damage | 1 | 2024 | 2472 | 0.460 |
Why?
|
| Receptors, Dopamine D2 | 3 | 2024 | 472 | 0.460 |
Why?
|
| Tumor Suppressor Proteins | 11 | 2022 | 2812 | 0.460 |
Why?
|
| Telomerase | 5 | 2023 | 753 | 0.450 |
Why?
|
| Radiotherapy, Adjuvant | 6 | 2015 | 1793 | 0.450 |
Why?
|
| DNA Methylation | 11 | 2023 | 4432 | 0.440 |
Why?
|
| Karnofsky Performance Status | 5 | 2019 | 167 | 0.440 |
Why?
|
| Medulloblastoma | 4 | 2022 | 683 | 0.440 |
Why?
|
| Nervous System | 3 | 2017 | 546 | 0.430 |
Why?
|
| Ganciclovir | 1 | 2014 | 256 | 0.430 |
Why?
|
| Sulfonamides | 5 | 2015 | 1981 | 0.430 |
Why?
|
| Drug Administration Schedule | 19 | 2018 | 4862 | 0.430 |
Why?
|
| Bayes Theorem | 7 | 2023 | 2360 | 0.420 |
Why?
|
| Quinoxalines | 1 | 2015 | 297 | 0.420 |
Why?
|
| Spinal Cord Neoplasms | 2 | 2021 | 264 | 0.420 |
Why?
|
| Periodicals as Topic | 2 | 2015 | 1470 | 0.420 |
Why?
|
| Pyrimidinones | 5 | 2023 | 386 | 0.420 |
Why?
|
| Venous Thromboembolism | 3 | 2019 | 1881 | 0.420 |
Why?
|
| Lymphoma, Non-Hodgkin | 4 | 2014 | 1376 | 0.420 |
Why?
|
| Oximes | 5 | 2022 | 303 | 0.410 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 8 | 2023 | 5434 | 0.400 |
Why?
|
| Clinical Trials, Phase III as Topic | 6 | 2020 | 878 | 0.400 |
Why?
|
| Drug Industry | 1 | 2019 | 793 | 0.400 |
Why?
|
| Integrins | 3 | 2015 | 843 | 0.390 |
Why?
|
| Electroencephalography | 7 | 2010 | 6317 | 0.380 |
Why?
|
| Neoplasm Staging | 22 | 2018 | 11262 | 0.380 |
Why?
|
| Piperazines | 5 | 2017 | 2553 | 0.370 |
Why?
|
| Thalidomide | 7 | 2011 | 886 | 0.370 |
Why?
|
| Radiopharmaceuticals | 5 | 2024 | 2734 | 0.370 |
Why?
|
| Drug Design | 2 | 2016 | 1046 | 0.370 |
Why?
|
| Genetic Heterogeneity | 1 | 2015 | 737 | 0.370 |
Why?
|
| Promoter Regions, Genetic | 15 | 2021 | 5801 | 0.360 |
Why?
|
| Gene Expression Regulation, Neoplastic | 9 | 2024 | 8664 | 0.350 |
Why?
|
| Attitude to Health | 1 | 2019 | 2025 | 0.350 |
Why?
|
| Drug Costs | 1 | 2019 | 1198 | 0.350 |
Why?
|
| Carcinoma, Small Cell | 4 | 2009 | 419 | 0.350 |
Why?
|
| Valproic Acid | 2 | 2021 | 444 | 0.350 |
Why?
|
| Central Nervous System Diseases | 2 | 2012 | 521 | 0.350 |
Why?
|
| Camptothecin | 8 | 2016 | 600 | 0.350 |
Why?
|
| Cerebral Hemorrhage | 6 | 2012 | 2660 | 0.350 |
Why?
|
| Synapses | 1 | 2020 | 1764 | 0.350 |
Why?
|
| Paraneoplastic Syndromes, Nervous System | 1 | 2010 | 24 | 0.340 |
Why?
|
| Receptors, Dopamine D5 | 2 | 2020 | 32 | 0.330 |
Why?
|
| Dendritic Cells | 2 | 2019 | 2748 | 0.330 |
Why?
|
| Drug Therapy | 2 | 2016 | 504 | 0.330 |
Why?
|
| Self Care | 1 | 2015 | 801 | 0.330 |
Why?
|
| Chromosomes, Human, Pair 1 | 5 | 2014 | 640 | 0.330 |
Why?
|
| Receptors, Somatostatin | 2 | 2024 | 138 | 0.330 |
Why?
|
| Benzhydryl Compounds | 1 | 2016 | 944 | 0.320 |
Why?
|
| Neoplasms, Second Primary | 4 | 2022 | 1060 | 0.320 |
Why?
|
| Scalp | 2 | 2010 | 391 | 0.320 |
Why?
|
| Rhabdoid Tumor | 2 | 2024 | 211 | 0.310 |
Why?
|
| Drug Therapy, Combination | 9 | 2017 | 6320 | 0.310 |
Why?
|
| Receptor Protein-Tyrosine Kinases | 5 | 2023 | 1629 | 0.310 |
Why?
|
| Meningeal Carcinomatosis | 3 | 2024 | 66 | 0.310 |
Why?
|
| Adolescent | 44 | 2025 | 89244 | 0.310 |
Why?
|
| Glutarates | 3 | 2019 | 243 | 0.300 |
Why?
|
| Animals | 70 | 2024 | 169335 | 0.300 |
Why?
|
| Contrast Media | 9 | 2020 | 5334 | 0.300 |
Why?
|
| Brain Damage, Chronic | 1 | 2009 | 267 | 0.300 |
Why?
|
| Recurrence | 16 | 2020 | 8513 | 0.290 |
Why?
|
| Benzoquinones | 1 | 2008 | 198 | 0.290 |
Why?
|
| Gene Expression Profiling | 9 | 2021 | 9549 | 0.290 |
Why?
|
| Connective Tissue | 1 | 2010 | 425 | 0.290 |
Why?
|
| Lymphoma | 4 | 2024 | 1900 | 0.290 |
Why?
|
| Drug Evaluation | 2 | 2008 | 642 | 0.290 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-2 | 4 | 2019 | 550 | 0.290 |
Why?
|
| Patient Preference | 1 | 2015 | 947 | 0.280 |
Why?
|
| Quinolones | 4 | 2017 | 389 | 0.280 |
Why?
|
| Cytomegalovirus Infections | 1 | 2014 | 839 | 0.280 |
Why?
|
| Skull | 2 | 2010 | 830 | 0.280 |
Why?
|
| Cohort Studies | 22 | 2024 | 41808 | 0.280 |
Why?
|
| Models, Anatomic | 2 | 2001 | 683 | 0.280 |
Why?
|
| Administration, Oral | 12 | 2024 | 4040 | 0.270 |
Why?
|
| Lactams, Macrocyclic | 1 | 2008 | 319 | 0.270 |
Why?
|
| Nitriles | 3 | 2024 | 990 | 0.270 |
Why?
|
| Publishing | 1 | 2014 | 837 | 0.270 |
Why?
|
| PTEN Phosphohydrolase | 6 | 2021 | 1120 | 0.270 |
Why?
|
| Intestinal Perforation | 1 | 2008 | 254 | 0.270 |
Why?
|
| Antigens, Neoplasm | 4 | 2024 | 2001 | 0.270 |
Why?
|
| Referral and Consultation | 1 | 2019 | 3628 | 0.260 |
Why?
|
| Brain Mapping | 3 | 2014 | 6739 | 0.260 |
Why?
|
| Models, Biological | 9 | 2021 | 9499 | 0.260 |
Why?
|
| Phosphotransferases | 1 | 2007 | 302 | 0.260 |
Why?
|
| Physician-Patient Relations | 1 | 2019 | 3269 | 0.260 |
Why?
|
| Nervous System Diseases | 2 | 2012 | 1665 | 0.260 |
Why?
|
| Lymphopenia | 3 | 2022 | 300 | 0.260 |
Why?
|
| Immunoconjugates | 3 | 2024 | 976 | 0.260 |
Why?
|
| Peptides | 2 | 2021 | 4353 | 0.260 |
Why?
|
| Quality of Life | 13 | 2024 | 13510 | 0.250 |
Why?
|
| HSP90 Heat-Shock Proteins | 1 | 2008 | 423 | 0.250 |
Why?
|
| Child | 32 | 2025 | 80960 | 0.250 |
Why?
|
| Paclitaxel | 1 | 2013 | 1735 | 0.250 |
Why?
|
| Drug Delivery Systems | 7 | 2024 | 2238 | 0.250 |
Why?
|
| Anisotropy | 4 | 2010 | 1295 | 0.240 |
Why?
|
| Thrombosis | 1 | 2019 | 2956 | 0.240 |
Why?
|
| Antiviral Agents | 2 | 2016 | 3070 | 0.240 |
Why?
|
| Random Allocation | 4 | 2023 | 2394 | 0.240 |
Why?
|
| Pinealoma | 1 | 2024 | 52 | 0.240 |
Why?
|
| Melanoma | 6 | 2023 | 5709 | 0.230 |
Why?
|
| Neoplasm Invasiveness | 3 | 2009 | 3629 | 0.230 |
Why?
|
| Ursodeoxycholic Acid | 1 | 2024 | 81 | 0.230 |
Why?
|
| Phenylurea Compounds | 3 | 2022 | 531 | 0.230 |
Why?
|
| Image Processing, Computer-Assisted | 8 | 2022 | 9080 | 0.230 |
Why?
|
| Anticoagulants | 5 | 2019 | 4850 | 0.230 |
Why?
|
| Comparative Genomic Hybridization | 6 | 2016 | 474 | 0.230 |
Why?
|
| Succinimides | 1 | 2024 | 83 | 0.230 |
Why?
|
| Gene Expression | 4 | 2018 | 7603 | 0.220 |
Why?
|
| Holography | 1 | 2024 | 80 | 0.220 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p16 | 2 | 2024 | 710 | 0.220 |
Why?
|
| Age Factors | 10 | 2024 | 18435 | 0.220 |
Why?
|
| Pineal Gland | 1 | 2024 | 158 | 0.220 |
Why?
|
| Cerebrovascular Disorders | 4 | 2015 | 1486 | 0.220 |
Why?
|
| Disease Management | 6 | 2025 | 2537 | 0.220 |
Why?
|
| Hepatocyte Growth Factor | 2 | 2018 | 269 | 0.220 |
Why?
|
| Snake Venoms | 2 | 2015 | 40 | 0.220 |
Why?
|
| Receptor, TIE-2 | 3 | 2019 | 183 | 0.220 |
Why?
|
| Nuclear Proteins | 6 | 2024 | 5804 | 0.220 |
Why?
|
| Proto-Oncogene Proteins c-met | 3 | 2019 | 567 | 0.210 |
Why?
|
| Stereotaxic Techniques | 7 | 1998 | 559 | 0.210 |
Why?
|
| Thiazoles | 1 | 2010 | 1542 | 0.210 |
Why?
|
| Microbubbles | 1 | 2024 | 137 | 0.210 |
Why?
|
| Gene Targeting | 1 | 2006 | 841 | 0.210 |
Why?
|
| Receptor, Platelet-Derived Growth Factor beta | 2 | 2017 | 183 | 0.210 |
Why?
|
| High-Throughput Nucleotide Sequencing | 5 | 2022 | 3671 | 0.210 |
Why?
|
| Ganglioglioma | 1 | 2022 | 36 | 0.210 |
Why?
|
| Breast Neoplasms | 10 | 2024 | 21188 | 0.210 |
Why?
|
| Rats | 26 | 2024 | 23786 | 0.210 |
Why?
|
| Finite Element Analysis | 3 | 2010 | 442 | 0.200 |
Why?
|
| Computer Simulation | 8 | 2025 | 6291 | 0.200 |
Why?
|
| Tumor Microenvironment | 8 | 2023 | 3952 | 0.200 |
Why?
|
| Receptors, AMPA | 2 | 2024 | 334 | 0.200 |
Why?
|
| Immunomodulation | 2 | 2017 | 549 | 0.200 |
Why?
|
| Boronic Acids | 5 | 2011 | 915 | 0.200 |
Why?
|
| Spinal Neoplasms | 2 | 2007 | 715 | 0.200 |
Why?
|
| Tuberous Sclerosis | 1 | 2010 | 1042 | 0.200 |
Why?
|
| Nerve Fibers, Myelinated | 1 | 2008 | 953 | 0.200 |
Why?
|
| Heart Transplantation | 3 | 2013 | 3301 | 0.200 |
Why?
|
| Temporal Lobe | 4 | 2019 | 1728 | 0.200 |
Why?
|
| Antineoplastic Agents, Phytogenic | 4 | 2012 | 622 | 0.200 |
Why?
|
| National Cancer Institute (U.S.) | 2 | 2021 | 300 | 0.200 |
Why?
|
| Cognition Disorders | 4 | 2011 | 3985 | 0.200 |
Why?
|
| Dentition, Permanent | 1 | 2021 | 22 | 0.200 |
Why?
|
| Observer Variation | 3 | 2019 | 2623 | 0.190 |
Why?
|
| Thromboembolism | 2 | 2002 | 1004 | 0.190 |
Why?
|
| Nitroimidazoles | 2 | 2021 | 118 | 0.190 |
Why?
|
| Uterine Cervical Neoplasms | 1 | 2014 | 2044 | 0.190 |
Why?
|
| Urogenital Neoplasms | 1 | 2003 | 132 | 0.190 |
Why?
|
| Tooth, Deciduous | 1 | 2021 | 76 | 0.190 |
Why?
|
| DNA, Neoplasm | 5 | 2022 | 1748 | 0.190 |
Why?
|
| Protein-Tyrosine Kinases | 3 | 2023 | 2433 | 0.190 |
Why?
|
| Germinoma | 1 | 2022 | 132 | 0.190 |
Why?
|
| Hepatitis B | 1 | 2007 | 711 | 0.190 |
Why?
|
| Double-Blind Method | 6 | 2024 | 12467 | 0.190 |
Why?
|
| Risk Assessment | 7 | 2025 | 24333 | 0.190 |
Why?
|
| Bone Marrow Transplantation | 3 | 2009 | 2709 | 0.190 |
Why?
|
| Phosphoramide Mustards | 1 | 2021 | 18 | 0.190 |
Why?
|
| Paraneoplastic Syndromes | 3 | 2003 | 154 | 0.190 |
Why?
|
| Genomics | 7 | 2024 | 5928 | 0.180 |
Why?
|
| Dexamethasone | 4 | 2022 | 1965 | 0.180 |
Why?
|
| Controlled Clinical Trials as Topic | 1 | 2021 | 187 | 0.180 |
Why?
|
| Pyrazines | 5 | 2011 | 1206 | 0.180 |
Why?
|
| Interleukin-12 | 2 | 2022 | 577 | 0.180 |
Why?
|
| Protein Kinases | 2 | 2006 | 1611 | 0.180 |
Why?
|
| Leukemia, Promyelocytic, Acute | 2 | 2008 | 249 | 0.180 |
Why?
|
| Algorithms | 9 | 2020 | 14201 | 0.180 |
Why?
|
| Immunoenzyme Techniques | 3 | 2015 | 1705 | 0.180 |
Why?
|
| Reproducibility of Results | 7 | 2023 | 20245 | 0.180 |
Why?
|
| Neoplastic Stem Cells | 4 | 2014 | 1356 | 0.180 |
Why?
|
| Medical Futility | 1 | 2022 | 136 | 0.180 |
Why?
|
| Societies | 1 | 2021 | 107 | 0.180 |
Why?
|
| alpha-Fetoproteins | 3 | 1998 | 229 | 0.180 |
Why?
|
| DNA Helicases | 2 | 2024 | 854 | 0.180 |
Why?
|
| Sterol Regulatory Element Binding Protein 1 | 2 | 2011 | 136 | 0.170 |
Why?
|
| Treatment Failure | 5 | 2017 | 2664 | 0.170 |
Why?
|
| Procarbazine | 3 | 2015 | 172 | 0.170 |
Why?
|
| Quinolines | 2 | 2016 | 772 | 0.170 |
Why?
|
| DNA Repair | 2 | 2024 | 2054 | 0.170 |
Why?
|
| Hydrazines | 1 | 2021 | 223 | 0.170 |
Why?
|
| Pyrroles | 3 | 2015 | 1125 | 0.170 |
Why?
|
| Molecular Imaging | 2 | 2024 | 826 | 0.170 |
Why?
|
| Palliative Care | 2 | 2014 | 3644 | 0.170 |
Why?
|
| Idoxuridine | 5 | 1998 | 111 | 0.170 |
Why?
|
| Cell Size | 1 | 2021 | 626 | 0.170 |
Why?
|
| Oncolytic Viruses | 1 | 2023 | 345 | 0.160 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-1 | 3 | 2019 | 560 | 0.160 |
Why?
|
| Polycystic Ovary Syndrome | 1 | 2024 | 383 | 0.160 |
Why?
|
| Granulocyte-Macrophage Colony-Stimulating Factor | 2 | 2016 | 892 | 0.160 |
Why?
|
| Biomedical Research | 1 | 2014 | 3463 | 0.160 |
Why?
|
| Action Potentials | 1 | 2006 | 1838 | 0.160 |
Why?
|
| Dictionaries as Topic | 1 | 2018 | 11 | 0.160 |
Why?
|
| Benzamides | 5 | 2019 | 1387 | 0.160 |
Why?
|
| Esophageal Neoplasms | 1 | 2009 | 1674 | 0.160 |
Why?
|
| Adjuvants, Immunologic | 2 | 2008 | 999 | 0.160 |
Why?
|
| Amphetamine-Related Disorders | 1 | 2019 | 80 | 0.160 |
Why?
|
| Neurosurgical Procedures | 6 | 2024 | 2110 | 0.160 |
Why?
|
| Periodontitis | 1 | 2024 | 577 | 0.150 |
Why?
|
| Radiation Tolerance | 2 | 2013 | 478 | 0.150 |
Why?
|
| United States Food and Drug Administration | 4 | 2021 | 1672 | 0.150 |
Why?
|
| Dermatitis, Exfoliative | 1 | 2018 | 27 | 0.150 |
Why?
|
| Biliary Tract Neoplasms | 1 | 2020 | 187 | 0.150 |
Why?
|
| Spinal Cord Compression | 4 | 2005 | 234 | 0.150 |
Why?
|
| Drug Screening Assays, Antitumor | 2 | 2021 | 719 | 0.150 |
Why?
|
| Pityriasis Rubra Pilaris | 1 | 2018 | 20 | 0.150 |
Why?
|
| Cell Line, Tumor | 14 | 2023 | 17173 | 0.150 |
Why?
|
| Drug Interactions | 6 | 2007 | 1418 | 0.150 |
Why?
|
| Cell Cycle Proteins | 4 | 2024 | 3450 | 0.150 |
Why?
|
| Magnetic Resonance Spectroscopy | 2 | 2018 | 3782 | 0.150 |
Why?
|
| Herpesvirus 1, Human | 1 | 2023 | 744 | 0.150 |
Why?
|
| Amphetamine | 1 | 2019 | 222 | 0.150 |
Why?
|
| Time Factors | 18 | 2020 | 40261 | 0.150 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2007 | 1811 | 0.150 |
Why?
|
| Polyradiculoneuropathy | 1 | 1997 | 65 | 0.150 |
Why?
|
| Histone Deacetylase Inhibitors | 2 | 2015 | 778 | 0.150 |
Why?
|
| Tumor Suppressor Protein p53 | 5 | 2021 | 2960 | 0.150 |
Why?
|
| Oncolytic Virotherapy | 1 | 2023 | 521 | 0.150 |
Why?
|
| Neutropenia | 2 | 2015 | 893 | 0.150 |
Why?
|
| Transcription Factors | 8 | 2024 | 12174 | 0.150 |
Why?
|
| Phentermine | 1 | 1997 | 31 | 0.140 |
Why?
|
| Fenfluramine | 1 | 1997 | 58 | 0.140 |
Why?
|
| Tomography, X-Ray Computed | 12 | 2016 | 20776 | 0.140 |
Why?
|
| Vincristine | 3 | 2015 | 1040 | 0.140 |
Why?
|
| Immunosuppressive Agents | 1 | 2010 | 4207 | 0.140 |
Why?
|
| Antibiotics, Antineoplastic | 2 | 2011 | 682 | 0.140 |
Why?
|
| Leukoencephalopathies | 2 | 2012 | 260 | 0.140 |
Why?
|
| Incidence | 12 | 2023 | 21547 | 0.140 |
Why?
|
| DNA Mutational Analysis | 5 | 2021 | 4124 | 0.140 |
Why?
|
| Excitatory Amino Acid Antagonists | 1 | 2020 | 451 | 0.140 |
Why?
|
| Chromosome Deletion | 2 | 2014 | 1390 | 0.140 |
Why?
|
| Pilot Projects | 5 | 2024 | 8748 | 0.140 |
Why?
|
| Evidence-Based Medicine | 4 | 2018 | 3709 | 0.140 |
Why?
|
| Benzylamines | 1 | 2018 | 251 | 0.140 |
Why?
|
| Laboratories | 1 | 2021 | 463 | 0.140 |
Why?
|
| Brachytherapy | 8 | 1998 | 1224 | 0.140 |
Why?
|
| Multiple Myeloma | 6 | 2011 | 5196 | 0.140 |
Why?
|
| Heterocyclic Compounds | 1 | 2018 | 245 | 0.140 |
Why?
|
| Heparin, Low-Molecular-Weight | 1 | 2019 | 344 | 0.140 |
Why?
|
| Neurosciences | 1 | 2022 | 385 | 0.140 |
Why?
|
| Necrosis | 5 | 2018 | 1620 | 0.140 |
Why?
|
| Appetite Depressants | 1 | 1997 | 108 | 0.140 |
Why?
|
| Histocompatibility Antigens Class II | 2 | 1992 | 1439 | 0.140 |
Why?
|
| Pituitary Neoplasms | 2 | 2016 | 1326 | 0.140 |
Why?
|
| Neoplasms, Germ Cell and Embryonal | 1 | 2022 | 496 | 0.140 |
Why?
|
| Micro-Electrical-Mechanical Systems | 1 | 2016 | 30 | 0.140 |
Why?
|
| Societies, Scientific | 1 | 2018 | 223 | 0.140 |
Why?
|
| Sarcoma | 3 | 2022 | 1806 | 0.130 |
Why?
|
| Medical Informatics Applications | 1 | 2018 | 180 | 0.130 |
Why?
|
| Single-Cell Analysis | 3 | 2024 | 2542 | 0.130 |
Why?
|
| Soft Tissue Injuries | 1 | 2018 | 173 | 0.130 |
Why?
|
| Nausea | 2 | 2017 | 682 | 0.130 |
Why?
|
| Proportional Hazards Models | 11 | 2023 | 12562 | 0.130 |
Why?
|
| Triazoles | 1 | 2021 | 904 | 0.130 |
Why?
|
| Imidazolines | 1 | 2015 | 18 | 0.130 |
Why?
|
| Rats, Sprague-Dawley | 8 | 2024 | 8144 | 0.130 |
Why?
|
| Glial Fibrillary Acidic Protein | 2 | 2015 | 564 | 0.130 |
Why?
|
| Immunohistochemistry | 13 | 2018 | 11116 | 0.130 |
Why?
|
| Metformin | 1 | 2023 | 909 | 0.130 |
Why?
|
| Guanine | 2 | 2016 | 280 | 0.130 |
Why?
|
| Patient Acceptance of Health Care | 2 | 2023 | 3235 | 0.130 |
Why?
|
| T-Lymphocytes | 7 | 2024 | 10276 | 0.130 |
Why?
|
| Neoplasm, Residual | 2 | 2018 | 1019 | 0.130 |
Why?
|
| Receptor, erbB-2 | 2 | 2024 | 2606 | 0.130 |
Why?
|
| Cytokines | 5 | 2019 | 7453 | 0.130 |
Why?
|
| Phantoms, Imaging | 1 | 2024 | 2533 | 0.130 |
Why?
|
| Lithium | 1 | 2019 | 600 | 0.130 |
Why?
|
| Testicular Neoplasms | 1 | 2022 | 808 | 0.130 |
Why?
|
| Protein Isoforms | 1 | 2020 | 1714 | 0.130 |
Why?
|
| STAT6 Transcription Factor | 1 | 2016 | 196 | 0.130 |
Why?
|
| L-Lactate Dehydrogenase | 2 | 2015 | 412 | 0.130 |
Why?
|
| Heart Septal Defects, Atrial | 1 | 2018 | 452 | 0.130 |
Why?
|
| Peroxynitrous Acid | 1 | 2015 | 40 | 0.120 |
Why?
|
| Antidepressive Agents | 1 | 2007 | 2913 | 0.120 |
Why?
|
| Stem Cells | 1 | 2008 | 3539 | 0.120 |
Why?
|
| Osteoblasts | 1 | 2021 | 1153 | 0.120 |
Why?
|
| Sulfones | 2 | 2022 | 448 | 0.120 |
Why?
|
| Postoperative Care | 2 | 2019 | 1481 | 0.120 |
Why?
|
| Mice | 26 | 2024 | 82072 | 0.120 |
Why?
|
| Leukopenia | 1 | 2015 | 212 | 0.120 |
Why?
|
| Receptors, Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 2015 | 115 | 0.120 |
Why?
|
| Gastrointestinal Neoplasms | 1 | 2003 | 957 | 0.120 |
Why?
|
| Awareness | 1 | 2019 | 653 | 0.120 |
Why?
|
| Neoplasm Metastasis | 7 | 2019 | 4926 | 0.120 |
Why?
|
| Lymphoma, B-Cell | 2 | 2013 | 945 | 0.120 |
Why?
|
| Thrombocytopenia | 2 | 2015 | 1181 | 0.120 |
Why?
|
| Hyperglycemia | 1 | 2023 | 1389 | 0.120 |
Why?
|
| Ankle | 1 | 2018 | 353 | 0.120 |
Why?
|
| Adenoma, Oxyphilic | 1 | 2016 | 152 | 0.120 |
Why?
|
| Xanthomatosis | 1 | 2014 | 32 | 0.120 |
Why?
|
| Headache | 2 | 2012 | 1264 | 0.120 |
Why?
|
| Cryopreservation | 1 | 2020 | 734 | 0.120 |
Why?
|
| Histocompatibility Antigens Class I | 2 | 1992 | 1363 | 0.120 |
Why?
|
| Supratentorial Neoplasms | 2 | 2010 | 159 | 0.120 |
Why?
|
| Prospective Studies | 16 | 2025 | 54962 | 0.120 |
Why?
|
| China | 4 | 2024 | 2395 | 0.120 |
Why?
|
| Societies, Medical | 3 | 2024 | 3968 | 0.120 |
Why?
|
| Caspase 8 | 1 | 2015 | 198 | 0.120 |
Why?
|
| Proto-Oncogene Proteins c-akt | 3 | 2016 | 2460 | 0.110 |
Why?
|
| Growth Inhibitors | 2 | 2006 | 375 | 0.110 |
Why?
|
| Tyrosine | 1 | 2018 | 1427 | 0.110 |
Why?
|
| Aspartate Aminotransferases | 1 | 2015 | 414 | 0.110 |
Why?
|
| Myoclonus | 1 | 1994 | 107 | 0.110 |
Why?
|
| Retreatment | 1 | 2015 | 600 | 0.110 |
Why?
|
| Neoplasms, Radiation-Induced | 2 | 2009 | 542 | 0.110 |
Why?
|
| Osteogenesis | 1 | 2021 | 1295 | 0.110 |
Why?
|
| Infertility, Female | 1 | 2020 | 764 | 0.110 |
Why?
|
| Information Dissemination | 2 | 2021 | 1141 | 0.110 |
Why?
|
| Phosphopyruvate Hydratase | 2 | 2015 | 128 | 0.110 |
Why?
|
| Ubiquitin Thiolesterase | 1 | 2017 | 465 | 0.110 |
Why?
|
| Semantics | 1 | 2017 | 618 | 0.110 |
Why?
|
| Lymphocytes | 3 | 1997 | 2614 | 0.110 |
Why?
|
| Caudate Nucleus | 1 | 2015 | 391 | 0.110 |
Why?
|
| Enzyme Activation | 2 | 2019 | 3588 | 0.110 |
Why?
|
| Neoplasms, Nerve Tissue | 1 | 2013 | 20 | 0.110 |
Why?
|
| Cysts | 1 | 2019 | 685 | 0.110 |
Why?
|
| Genotype | 5 | 2017 | 13048 | 0.110 |
Why?
|
| Pancreatic Polypeptide-Secreting Cells | 1 | 2013 | 2 | 0.110 |
Why?
|
| North America | 4 | 2011 | 1290 | 0.110 |
Why?
|
| Travel | 1 | 2019 | 805 | 0.110 |
Why?
|
| Image Enhancement | 4 | 2018 | 2898 | 0.110 |
Why?
|
| Antimetabolites, Antineoplastic | 2 | 2013 | 647 | 0.110 |
Why?
|
| Adenocarcinoma | 3 | 2023 | 6401 | 0.110 |
Why?
|
| Proto-Oncogene Proteins c-mdm2 | 1 | 2015 | 362 | 0.110 |
Why?
|
| Transplantation, Heterotopic | 1 | 2013 | 175 | 0.110 |
Why?
|
| Cyclin-Dependent Kinase 6 | 1 | 2016 | 354 | 0.110 |
Why?
|
| Remission Induction | 4 | 2015 | 2408 | 0.110 |
Why?
|
| Mice, Nude | 4 | 2019 | 3631 | 0.110 |
Why?
|
| Ocular Motility Disorders | 1 | 1994 | 144 | 0.100 |
Why?
|
| Gene Fusion | 1 | 2016 | 357 | 0.100 |
Why?
|
| Minority Groups | 1 | 2020 | 1216 | 0.100 |
Why?
|
| Alanine Transaminase | 1 | 2015 | 606 | 0.100 |
Why?
|
| Artificial Intelligence | 2 | 2024 | 2666 | 0.100 |
Why?
|
| Congresses as Topic | 1 | 2018 | 812 | 0.100 |
Why?
|
| Mesangial Cells | 1 | 2012 | 23 | 0.100 |
Why?
|
| Iodine Radioisotopes | 5 | 1998 | 1034 | 0.100 |
Why?
|
| MutS Homolog 2 Protein | 1 | 2013 | 200 | 0.100 |
Why?
|
| Fibronectins | 2 | 2015 | 724 | 0.100 |
Why?
|
| Caspase 3 | 1 | 2015 | 731 | 0.100 |
Why?
|
| Europe | 1 | 2019 | 3441 | 0.100 |
Why?
|
| Decision Trees | 1 | 2014 | 509 | 0.100 |
Why?
|
| Cyclin-Dependent Kinase 4 | 1 | 2016 | 566 | 0.100 |
Why?
|
| Chromosomes, Human, Pair 19 | 2 | 2012 | 350 | 0.100 |
Why?
|
| Neuroprotective Agents | 2 | 2019 | 958 | 0.100 |
Why?
|
| Genetic Vectors | 7 | 1998 | 3412 | 0.100 |
Why?
|
| Liver Transplantation | 1 | 2024 | 2403 | 0.100 |
Why?
|
| Glutamates | 1 | 2013 | 385 | 0.100 |
Why?
|
| Lab-On-A-Chip Devices | 1 | 2016 | 446 | 0.100 |
Why?
|
| src-Family Kinases | 1 | 2014 | 539 | 0.100 |
Why?
|
| Cognition | 3 | 2016 | 7081 | 0.100 |
Why?
|
| Constipation | 2 | 2015 | 570 | 0.100 |
Why?
|
| DNA Fragmentation | 1 | 2012 | 240 | 0.100 |
Why?
|
| Educational Status | 1 | 2019 | 2515 | 0.100 |
Why?
|
| Enzyme Induction | 3 | 2007 | 455 | 0.100 |
Why?
|
| Polymerase Chain Reaction | 5 | 2015 | 6086 | 0.100 |
Why?
|
| Ethical Analysis | 1 | 2011 | 41 | 0.100 |
Why?
|
| Matrix Metalloproteinase 9 | 1 | 2015 | 633 | 0.100 |
Why?
|
| Proteins | 2 | 2014 | 6011 | 0.100 |
Why?
|
| Child, Preschool | 10 | 2024 | 42683 | 0.100 |
Why?
|
| Drug Eruptions | 3 | 2014 | 335 | 0.090 |
Why?
|
| Emergencies | 1 | 1998 | 1221 | 0.090 |
Why?
|
| Erythropoietin | 2 | 2014 | 718 | 0.090 |
Why?
|
| Hepatitis B, Chronic | 1 | 2016 | 413 | 0.090 |
Why?
|
| Propionates | 1 | 2012 | 180 | 0.090 |
Why?
|
| Learning Curve | 1 | 2013 | 232 | 0.090 |
Why?
|
| Phenotype | 6 | 2023 | 16731 | 0.090 |
Why?
|
| Orphan Nuclear Receptors | 1 | 2011 | 63 | 0.090 |
Why?
|
| Nerve Tissue Proteins | 2 | 2014 | 4413 | 0.090 |
Why?
|
| SEER Program | 4 | 2021 | 1473 | 0.090 |
Why?
|
| Parietal Lobe | 2 | 2016 | 866 | 0.090 |
Why?
|
| Organ Transplantation | 1 | 2001 | 1178 | 0.090 |
Why?
|
| Neoplasms, Experimental | 1 | 2016 | 1231 | 0.090 |
Why?
|
| Diagnostic Tests, Routine | 1 | 2017 | 790 | 0.090 |
Why?
|
| Adenoviruses, Human | 3 | 1998 | 257 | 0.090 |
Why?
|
| Stress, Physiological | 1 | 2019 | 1408 | 0.090 |
Why?
|
| Meningitis | 1 | 1993 | 219 | 0.090 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 2 | 2008 | 1658 | 0.090 |
Why?
|
| Acetamides | 1 | 2013 | 260 | 0.090 |
Why?
|
| Caregivers | 1 | 2023 | 2308 | 0.090 |
Why?
|
| Cell Lineage | 2 | 2024 | 2576 | 0.090 |
Why?
|
| Up-Regulation | 4 | 2019 | 4148 | 0.090 |
Why?
|
| Lamivudine | 2 | 2016 | 367 | 0.090 |
Why?
|
| Neoplasm Transplantation | 8 | 2016 | 2018 | 0.090 |
Why?
|
| Predictive Value of Tests | 9 | 2020 | 15471 | 0.090 |
Why?
|
| Benzimidazoles | 1 | 2016 | 864 | 0.090 |
Why?
|
| Genetic Testing | 2 | 2014 | 3591 | 0.090 |
Why?
|
| Rats, Inbred F344 | 10 | 1998 | 825 | 0.090 |
Why?
|
| Depsipeptides | 1 | 2011 | 96 | 0.090 |
Why?
|
| Histocompatibility Antigens | 1 | 1992 | 479 | 0.090 |
Why?
|
| Interferon-gamma | 3 | 2019 | 3163 | 0.090 |
Why?
|
| Burkitt Lymphoma | 1 | 1993 | 338 | 0.090 |
Why?
|
| Hemangioendothelioma, Epithelioid | 1 | 2011 | 54 | 0.090 |
Why?
|
| Central Nervous System Stimulants | 1 | 2019 | 1170 | 0.090 |
Why?
|
| Molecular Diagnostic Techniques | 1 | 2015 | 620 | 0.090 |
Why?
|
| Niacinamide | 1 | 2012 | 418 | 0.090 |
Why?
|
| Drug Synergism | 3 | 2011 | 1762 | 0.090 |
Why?
|
| Immunocompromised Host | 2 | 2024 | 863 | 0.090 |
Why?
|
| Hematopoietic Stem Cell Mobilization | 1 | 2011 | 225 | 0.090 |
Why?
|
| Radiotherapy Planning, Computer-Assisted | 1 | 2019 | 1679 | 0.090 |
Why?
|
| von Hippel-Lindau Disease | 1 | 2011 | 154 | 0.090 |
Why?
|
| Cell Death | 2 | 2015 | 1682 | 0.080 |
Why?
|
| Lymphoma, AIDS-Related | 1 | 2010 | 79 | 0.080 |
Why?
|
| Guidelines as Topic | 3 | 2016 | 1399 | 0.080 |
Why?
|
| Keratin-13 | 1 | 2009 | 11 | 0.080 |
Why?
|
| Risk Factors | 9 | 2019 | 74976 | 0.080 |
Why?
|
| Tumor Stem Cell Assay | 1 | 2009 | 116 | 0.080 |
Why?
|
| Freeze Drying | 1 | 2009 | 97 | 0.080 |
Why?
|
| Drug Approval | 2 | 2014 | 821 | 0.080 |
Why?
|
| Chromogranin A | 1 | 2009 | 47 | 0.080 |
Why?
|
| Biophysical Phenomena | 1 | 2010 | 320 | 0.080 |
Why?
|
| Cyclophosphamide | 3 | 2010 | 2227 | 0.080 |
Why?
|
| Models, Animal | 2 | 2013 | 2122 | 0.080 |
Why?
|
| DNA Copy Number Variations | 2 | 2015 | 2055 | 0.080 |
Why?
|
| Spinal Cord Diseases | 1 | 1992 | 293 | 0.080 |
Why?
|
| Cell Proliferation | 7 | 2024 | 10486 | 0.080 |
Why?
|
| Synaptophysin | 1 | 2009 | 138 | 0.080 |
Why?
|
| Surgical Flaps | 1 | 2018 | 1682 | 0.080 |
Why?
|
| MAP Kinase Signaling System | 1 | 2016 | 1495 | 0.080 |
Why?
|
| Patient Participation | 1 | 2018 | 1448 | 0.080 |
Why?
|
| Aniline Compounds | 1 | 2014 | 1095 | 0.080 |
Why?
|
| In Situ Hybridization, Fluorescence | 5 | 2015 | 2525 | 0.080 |
Why?
|
| Consensus Development Conferences as Topic | 1 | 2009 | 169 | 0.080 |
Why?
|
| Hemoglobins | 1 | 2015 | 1531 | 0.080 |
Why?
|
| Stochastic Processes | 1 | 2010 | 360 | 0.080 |
Why?
|
| Receptors, LDL | 1 | 2011 | 492 | 0.080 |
Why?
|
| Diarrhea | 1 | 2015 | 1320 | 0.080 |
Why?
|
| Hemangiosarcoma | 1 | 2011 | 215 | 0.080 |
Why?
|
| Platelet Count | 1 | 2011 | 787 | 0.080 |
Why?
|
| Endothelial Cells | 3 | 2011 | 3592 | 0.080 |
Why?
|
| Cluster Analysis | 5 | 2019 | 2732 | 0.080 |
Why?
|
| Xenograft Model Antitumor Assays | 4 | 2020 | 3621 | 0.080 |
Why?
|
| Thyroid Neoplasms | 1 | 2022 | 2360 | 0.080 |
Why?
|
| Placebos | 2 | 2020 | 1667 | 0.080 |
Why?
|
| Hematologic Tests | 1 | 2009 | 239 | 0.080 |
Why?
|
| Electronic Health Records | 2 | 2023 | 4879 | 0.080 |
Why?
|
| Oligodeoxyribonucleotides | 2 | 2008 | 706 | 0.080 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 1 | 2016 | 1769 | 0.080 |
Why?
|
| Gene Deletion | 4 | 2012 | 2674 | 0.070 |
Why?
|
| Prevalence | 3 | 2021 | 15879 | 0.070 |
Why?
|
| Spinal Nerves | 1 | 2008 | 92 | 0.070 |
Why?
|
| Models, Theoretical | 2 | 2019 | 3580 | 0.070 |
Why?
|
| Drug Monitoring | 3 | 2020 | 965 | 0.070 |
Why?
|
| Neurofibromatosis 2 | 1 | 2011 | 388 | 0.070 |
Why?
|
| Genetic Predisposition to Disease | 3 | 2016 | 18068 | 0.070 |
Why?
|
| Healthcare Disparities | 2 | 2024 | 3421 | 0.070 |
Why?
|
| Vaccines, Subunit | 1 | 2008 | 159 | 0.070 |
Why?
|
| O(6)-Methylguanine-DNA Methyltransferase | 1 | 2008 | 83 | 0.070 |
Why?
|
| Atrophy | 1 | 2013 | 1647 | 0.070 |
Why?
|
| United States | 9 | 2024 | 73186 | 0.070 |
Why?
|
| Etanidazole | 3 | 1998 | 22 | 0.070 |
Why?
|
| Lipogenesis | 1 | 2009 | 216 | 0.070 |
Why?
|
| Amyloid Precursor Protein Secretases | 1 | 2012 | 614 | 0.070 |
Why?
|
| Cytotoxins | 1 | 2008 | 154 | 0.070 |
Why?
|
| Fibroblast Growth Factor 2 | 2 | 2008 | 594 | 0.070 |
Why?
|
| Basic Helix-Loop-Helix Transcription Factors | 1 | 2014 | 1143 | 0.070 |
Why?
|
| Receptor, Platelet-Derived Growth Factor alpha | 1 | 2009 | 368 | 0.070 |
Why?
|
| Phthalazines | 1 | 2010 | 397 | 0.070 |
Why?
|
| Depression | 1 | 2007 | 8231 | 0.070 |
Why?
|
| Keratins | 1 | 2009 | 502 | 0.070 |
Why?
|
| Blood Vessels | 1 | 2013 | 1110 | 0.070 |
Why?
|
| Endostatins | 1 | 2008 | 168 | 0.070 |
Why?
|
| Gelatin | 1 | 2009 | 231 | 0.070 |
Why?
|
| Nitrosourea Compounds | 1 | 2007 | 32 | 0.070 |
Why?
|
| Drug Discovery | 1 | 2015 | 1068 | 0.070 |
Why?
|
| Brain Diseases | 2 | 1994 | 1558 | 0.070 |
Why?
|
| Blotting, Western | 3 | 2015 | 5033 | 0.070 |
Why?
|
| Malondialdehyde | 3 | 1995 | 113 | 0.070 |
Why?
|
| Ligands | 2 | 2024 | 3283 | 0.070 |
Why?
|
| Thrombospondins | 1 | 2008 | 196 | 0.070 |
Why?
|
| Carmustine | 3 | 2014 | 137 | 0.070 |
Why?
|
| Topotecan | 1 | 2007 | 131 | 0.070 |
Why?
|
| Antineoplastic Protocols | 1 | 2007 | 48 | 0.070 |
Why?
|
| Fatal Outcome | 6 | 2010 | 1836 | 0.070 |
Why?
|
| Benchmarking | 1 | 2014 | 1059 | 0.070 |
Why?
|
| Diverticulitis | 1 | 2010 | 187 | 0.070 |
Why?
|
| Tumor Cells, Cultured | 10 | 1999 | 6131 | 0.070 |
Why?
|
| Dehydroepiandrosterone Sulfate | 2 | 1998 | 241 | 0.070 |
Why?
|
| Mice, SCID | 2 | 2011 | 2631 | 0.070 |
Why?
|
| Stathmin | 1 | 2007 | 70 | 0.070 |
Why?
|
| Pyrazoles | 2 | 2008 | 2029 | 0.070 |
Why?
|
| Carbazoles | 1 | 2008 | 230 | 0.070 |
Why?
|
| Cell Differentiation | 2 | 2024 | 11684 | 0.070 |
Why?
|
| Diagnosis, Differential | 7 | 2014 | 13021 | 0.070 |
Why?
|
| Chromosome Aberrations | 2 | 2011 | 1780 | 0.070 |
Why?
|
| Insulin-Like Growth Factor I | 1 | 2014 | 1943 | 0.070 |
Why?
|
| Area Under Curve | 5 | 2016 | 1645 | 0.070 |
Why?
|
| Databases, Factual | 3 | 2021 | 8094 | 0.070 |
Why?
|
| Magnetic Resonance Angiography | 1 | 2013 | 1434 | 0.070 |
Why?
|
| Image Interpretation, Computer-Assisted | 4 | 2017 | 3411 | 0.070 |
Why?
|
| Disease Models, Animal | 9 | 2016 | 18354 | 0.070 |
Why?
|
| Loss of Heterozygosity | 1 | 2009 | 663 | 0.070 |
Why?
|
| Endocrine System Diseases | 1 | 2009 | 250 | 0.070 |
Why?
|
| Chemokine CCL2 | 2 | 2001 | 606 | 0.070 |
Why?
|
| Cerebral Arteries | 1 | 2008 | 489 | 0.070 |
Why?
|
| Antibodies | 1 | 1994 | 2422 | 0.070 |
Why?
|
| Ethics, Medical | 1 | 2011 | 785 | 0.070 |
Why?
|
| Proto-Oncogene Proteins | 4 | 2023 | 4528 | 0.070 |
Why?
|
| Liver | 3 | 2007 | 7578 | 0.070 |
Why?
|
| Brain Stem Neoplasms | 1 | 2008 | 191 | 0.070 |
Why?
|
| Farnesyltranstransferase | 1 | 2006 | 71 | 0.070 |
Why?
|
| Internal Medicine | 2 | 2024 | 1064 | 0.060 |
Why?
|
| Neuropsychological Tests | 2 | 2017 | 7148 | 0.060 |
Why?
|
| Pancreas | 1 | 2013 | 1700 | 0.060 |
Why?
|
| Echocardiography | 1 | 2018 | 5047 | 0.060 |
Why?
|
| Aneuploidy | 1 | 2009 | 573 | 0.060 |
Why?
|
| Health Services Accessibility | 1 | 2023 | 5522 | 0.060 |
Why?
|
| Statistics, Nonparametric | 4 | 2016 | 2862 | 0.060 |
Why?
|
| Ricin | 2 | 1997 | 70 | 0.060 |
Why?
|
| Cartilage | 1 | 2009 | 811 | 0.060 |
Why?
|
| Etoposide | 1 | 2007 | 639 | 0.060 |
Why?
|
| RNA-Binding Proteins | 1 | 1994 | 1891 | 0.060 |
Why?
|
| Liver Cirrhosis | 1 | 2016 | 1962 | 0.060 |
Why?
|
| Esophagectomy | 1 | 2009 | 482 | 0.060 |
Why?
|
| Albumins | 2 | 2000 | 577 | 0.060 |
Why?
|
| Interleukins | 1 | 2010 | 796 | 0.060 |
Why?
|
| Fenretinide | 1 | 2004 | 9 | 0.060 |
Why?
|
| Interferons | 1 | 1989 | 720 | 0.060 |
Why?
|
| Immunotoxins | 2 | 1997 | 175 | 0.060 |
Why?
|
| Virus Activation | 1 | 2007 | 324 | 0.060 |
Why?
|
| Leukemia Inhibitory Factor | 1 | 2005 | 81 | 0.060 |
Why?
|
| Repressor Proteins | 1 | 2016 | 2986 | 0.060 |
Why?
|
| Hypertension | 2 | 2015 | 8617 | 0.060 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p15 | 1 | 2024 | 76 | 0.060 |
Why?
|
| Cell Cycle | 2 | 2011 | 2937 | 0.060 |
Why?
|
| Renal Dialysis | 1 | 2014 | 1789 | 0.060 |
Why?
|
| Hydroxylamines | 1 | 2024 | 39 | 0.060 |
Why?
|
| Superoxide Dismutase | 3 | 1995 | 595 | 0.060 |
Why?
|
| Cholagogues and Choleretics | 1 | 2024 | 39 | 0.060 |
Why?
|
| Odds Ratio | 3 | 2017 | 9684 | 0.060 |
Why?
|
| Chloramphenicol O-Acetyltransferase | 3 | 1994 | 221 | 0.060 |
Why?
|
| Endorphins | 1 | 1984 | 73 | 0.060 |
Why?
|
| Comorbidity | 1 | 2019 | 10592 | 0.060 |
Why?
|
| Interleukin-6 | 2 | 2024 | 3232 | 0.060 |
Why?
|
| beta-Galactosidase | 4 | 1998 | 575 | 0.060 |
Why?
|
| Myocardium | 2 | 2013 | 4790 | 0.060 |
Why?
|
| Dynorphins | 1 | 1984 | 82 | 0.060 |
Why?
|
| Growth Substances | 1 | 2006 | 760 | 0.060 |
Why?
|
| Matrix Metalloproteinase 8 | 1 | 2024 | 57 | 0.060 |
Why?
|
| Stem Cell Transplantation | 2 | 2009 | 1602 | 0.060 |
Why?
|
| Reverse Transcriptase Inhibitors | 1 | 2007 | 622 | 0.060 |
Why?
|
| Gene Dosage | 2 | 2020 | 1222 | 0.050 |
Why?
|
| Heroin | 1 | 1984 | 120 | 0.050 |
Why?
|
| Radiography | 4 | 2011 | 6991 | 0.050 |
Why?
|
| Gene Expression Regulation | 4 | 2019 | 11932 | 0.050 |
Why?
|
| Survivors | 1 | 2014 | 2383 | 0.050 |
Why?
|
| Claudins | 1 | 2024 | 117 | 0.050 |
Why?
|
| Risk | 2 | 2015 | 9621 | 0.050 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 2016 | 4413 | 0.050 |
Why?
|
| Deglutition Disorders | 1 | 2009 | 641 | 0.050 |
Why?
|
| Transducers | 1 | 2024 | 245 | 0.050 |
Why?
|
| Radiotherapy Dosage | 5 | 2019 | 2921 | 0.050 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 4 | 2013 | 3813 | 0.050 |
Why?
|
| Radioisotopes | 1 | 2024 | 517 | 0.050 |
Why?
|
| Lymph Node Excision | 1 | 2009 | 1273 | 0.050 |
Why?
|
| Organoplatinum Compounds | 2 | 2018 | 408 | 0.050 |
Why?
|
| Meta-Analysis as Topic | 1 | 2008 | 1364 | 0.050 |
Why?
|
| Isotope Labeling | 1 | 2024 | 395 | 0.050 |
Why?
|
| Migraine Disorders | 1 | 1995 | 1713 | 0.050 |
Why?
|
| Acoustics | 1 | 2024 | 244 | 0.050 |
Why?
|
| Hippocampus | 1 | 1995 | 3782 | 0.050 |
Why?
|
| Lipase | 1 | 2005 | 321 | 0.050 |
Why?
|
| Circadian Rhythm | 1 | 2014 | 2593 | 0.050 |
Why?
|
| Ontario | 1 | 2023 | 403 | 0.050 |
Why?
|
| Gastrointestinal Hemorrhage | 1 | 2010 | 1126 | 0.050 |
Why?
|
| Adaptor Proteins, Signal Transducing | 1 | 2013 | 2911 | 0.050 |
Why?
|
| Enhancer Elements, Genetic | 3 | 2000 | 1369 | 0.050 |
Why?
|
| Molecular Biology | 3 | 2012 | 573 | 0.050 |
Why?
|
| Genetic Variation | 1 | 2017 | 6611 | 0.050 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2016 | 4651 | 0.050 |
Why?
|
| Skull Neoplasms | 1 | 2003 | 173 | 0.050 |
Why?
|
| Neuroendocrine Tumors | 1 | 2008 | 657 | 0.050 |
Why?
|
| Graft vs Host Disease | 2 | 2009 | 3048 | 0.050 |
Why?
|
| Oxygen | 1 | 2013 | 4272 | 0.050 |
Why?
|
| Delivery of Health Care | 1 | 2020 | 5375 | 0.050 |
Why?
|
| Receptor, Fibroblast Growth Factor, Type 3 | 1 | 2022 | 109 | 0.050 |
Why?
|
| Follicle Stimulating Hormone | 1 | 2024 | 727 | 0.050 |
Why?
|
| Platinum Compounds | 1 | 2022 | 95 | 0.050 |
Why?
|
| Dopamine Agonists | 1 | 2024 | 347 | 0.050 |
Why?
|
| Brain Ischemia | 1 | 2015 | 3008 | 0.050 |
Why?
|
| Misonidazole | 1 | 2021 | 33 | 0.050 |
Why?
|
| Nervous System Physiological Phenomena | 1 | 2022 | 114 | 0.050 |
Why?
|
| Luteinizing Hormone | 1 | 2024 | 822 | 0.050 |
Why?
|
| 5'-Nucleotidase | 1 | 2022 | 164 | 0.050 |
Why?
|
| Pulmonary Embolism | 2 | 2011 | 2600 | 0.050 |
Why?
|
| Transfection | 7 | 1997 | 5763 | 0.050 |
Why?
|
| International Agencies | 2 | 2012 | 244 | 0.050 |
Why?
|
| Biocompatible Materials | 1 | 2009 | 1703 | 0.050 |
Why?
|
| Adipocytes | 2 | 1998 | 1199 | 0.050 |
Why?
|
| Receptor, Notch1 | 1 | 2024 | 520 | 0.050 |
Why?
|
| Nuclear Medicine | 1 | 2024 | 262 | 0.050 |
Why?
|
| Patient Care Planning | 1 | 2006 | 904 | 0.040 |
Why?
|
| Intention | 1 | 2023 | 348 | 0.040 |
Why?
|
| Genome, Human | 2 | 2020 | 4456 | 0.040 |
Why?
|
| Echo-Planar Imaging | 2 | 2014 | 674 | 0.040 |
Why?
|
| Hodgkin Disease | 1 | 2008 | 1384 | 0.040 |
Why?
|
| Evoked Potentials | 1 | 2006 | 1058 | 0.040 |
Why?
|
| Ventricular Function, Left | 1 | 2013 | 3941 | 0.040 |
Why?
|
| Biomarkers, Pharmacological | 1 | 2021 | 162 | 0.040 |
Why?
|
| Ribonuclease III | 1 | 2022 | 271 | 0.040 |
Why?
|
| Ki-67 Antigen | 1 | 2022 | 628 | 0.040 |
Why?
|
| Standard of Care | 2 | 2017 | 569 | 0.040 |
Why?
|
| DNA, Viral | 1 | 2007 | 2205 | 0.040 |
Why?
|
| Neurofibromin 1 | 1 | 2021 | 190 | 0.040 |
Why?
|
| Organotechnetium Compounds | 2 | 1997 | 133 | 0.040 |
Why?
|
| Feedback | 1 | 2023 | 799 | 0.040 |
Why?
|
| Receptors, Progesterone | 1 | 2024 | 1159 | 0.040 |
Why?
|
| Multivariate Analysis | 5 | 2015 | 12095 | 0.040 |
Why?
|
| Progesterone | 1 | 2024 | 752 | 0.040 |
Why?
|
| Models, Statistical | 3 | 2023 | 5110 | 0.040 |
Why?
|
| Carcinoma, Giant Cell | 1 | 1999 | 5 | 0.040 |
Why?
|
| Mathematics | 1 | 2000 | 704 | 0.040 |
Why?
|
| Tissue Engineering | 1 | 2009 | 1893 | 0.040 |
Why?
|
| Genome-Wide Association Study | 2 | 2017 | 12801 | 0.040 |
Why?
|
| Biomedical Engineering | 1 | 2000 | 286 | 0.040 |
Why?
|
| Cerebral Cortex | 1 | 1995 | 5831 | 0.040 |
Why?
|
| Substance Withdrawal Syndrome | 1 | 1984 | 628 | 0.040 |
Why?
|
| Hemorrhage | 1 | 2011 | 3466 | 0.040 |
Why?
|
| DEAD-box RNA Helicases | 1 | 2022 | 385 | 0.040 |
Why?
|
| Cyclic N-Oxides | 2 | 1995 | 72 | 0.040 |
Why?
|
| DNA | 3 | 2023 | 7214 | 0.040 |
Why?
|
| Sequence Analysis, DNA | 3 | 2020 | 4785 | 0.040 |
Why?
|
| Electron Spin Resonance Spectroscopy | 2 | 1995 | 161 | 0.040 |
Why?
|
| Partnership Practice | 1 | 2018 | 14 | 0.040 |
Why?
|
| Nitrogen Oxides | 2 | 1995 | 128 | 0.040 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 3 | 2015 | 3810 | 0.040 |
Why?
|
| International Cooperation | 2 | 2018 | 1436 | 0.040 |
Why?
|
| CDC2 Protein Kinase | 1 | 2019 | 212 | 0.040 |
Why?
|
| Free Radicals | 2 | 1995 | 238 | 0.040 |
Why?
|
| Blood Pressure | 1 | 2014 | 8544 | 0.040 |
Why?
|
| Propensity Score | 2 | 2017 | 1968 | 0.040 |
Why?
|
| Epidural Neoplasms | 1 | 1998 | 24 | 0.040 |
Why?
|
| Nucleic Acid Synthesis Inhibitors | 1 | 1998 | 109 | 0.040 |
Why?
|
| Receptor, Fibroblast Growth Factor, Type 1 | 1 | 2019 | 260 | 0.040 |
Why?
|
| Mitogen-Activated Protein Kinase Kinases | 1 | 2021 | 637 | 0.040 |
Why?
|
| Polymorphism, Single Nucleotide | 2 | 2015 | 16053 | 0.040 |
Why?
|
| Ecosystem | 1 | 2022 | 494 | 0.040 |
Why?
|
| Trans-Activators | 2 | 2001 | 2858 | 0.040 |
Why?
|
| Canada | 1 | 2023 | 2130 | 0.040 |
Why?
|
| Binding, Competitive | 2 | 2001 | 1142 | 0.040 |
Why?
|
| Microsatellite Repeats | 1 | 2020 | 785 | 0.040 |
Why?
|
| Bronchopulmonary Sequestration | 1 | 1997 | 43 | 0.040 |
Why?
|
| Epigenomics | 1 | 2023 | 961 | 0.040 |
Why?
|
| Neoplasm Seeding | 1 | 2018 | 85 | 0.040 |
Why?
|
| Triazines | 1 | 2019 | 311 | 0.040 |
Why?
|
| Viral Load | 1 | 2007 | 3398 | 0.040 |
Why?
|
| Deoxycytidine | 1 | 2002 | 888 | 0.040 |
Why?
|
| Amino Acids | 1 | 2024 | 1716 | 0.040 |
Why?
|
| Adenosine | 1 | 2022 | 822 | 0.040 |
Why?
|
| Dehydroepiandrosterone | 1 | 1998 | 259 | 0.040 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 2 | 2015 | 1105 | 0.040 |
Why?
|
| Drug Repositioning | 1 | 2019 | 246 | 0.040 |
Why?
|
| Spin Labels | 2 | 1995 | 339 | 0.040 |
Why?
|
| Carboplatin | 1 | 2020 | 799 | 0.030 |
Why?
|
| Automation | 1 | 2019 | 589 | 0.030 |
Why?
|
| Telomere | 1 | 2023 | 943 | 0.030 |
Why?
|
| Microtubule-Associated Proteins | 1 | 2022 | 1074 | 0.030 |
Why?
|
| Ovarian Neoplasms | 1 | 2014 | 4919 | 0.030 |
Why?
|
| DNA Mismatch Repair | 1 | 2020 | 432 | 0.030 |
Why?
|
| Base Sequence | 5 | 2007 | 12430 | 0.030 |
Why?
|
| Platelet Factor 4 | 1 | 1997 | 132 | 0.030 |
Why?
|
| Cytochrome P-450 CYP2B1 | 1 | 1996 | 22 | 0.030 |
Why?
|
| Protein Binding | 3 | 2018 | 9344 | 0.030 |
Why?
|
| Lymphatic Metastasis | 2 | 2017 | 2916 | 0.030 |
Why?
|
| Deoxycytidine Kinase | 1 | 1996 | 11 | 0.030 |
Why?
|
| Postoperative Period | 1 | 2021 | 1830 | 0.030 |
Why?
|
| Clinical Protocols | 2 | 2015 | 1445 | 0.030 |
Why?
|
| Flucytosine | 1 | 1996 | 33 | 0.030 |
Why?
|
| Nucleoside Deaminases | 1 | 1996 | 58 | 0.030 |
Why?
|
| Cities | 1 | 2019 | 543 | 0.030 |
Why?
|
| Probability | 1 | 2022 | 2483 | 0.030 |
Why?
|
| Technetium Tc 99m Sestamibi | 1 | 1997 | 184 | 0.030 |
Why?
|
| Reference Standards | 1 | 2020 | 1014 | 0.030 |
Why?
|
| 4-1BB Ligand | 1 | 2016 | 29 | 0.030 |
Why?
|
| Defective Viruses | 1 | 1996 | 89 | 0.030 |
Why?
|
| Cadherins | 1 | 2001 | 906 | 0.030 |
Why?
|
| Astrocytes | 1 | 2024 | 1349 | 0.030 |
Why?
|
| OX40 Ligand | 1 | 2016 | 57 | 0.030 |
Why?
|
| Mutagenesis | 1 | 2020 | 1229 | 0.030 |
Why?
|
| Thymidine | 1 | 2016 | 297 | 0.030 |
Why?
|
| Carcinoma, Renal Cell | 1 | 2011 | 3200 | 0.030 |
Why?
|
| Embryo Transfer | 1 | 2020 | 527 | 0.030 |
Why?
|
| Feasibility Studies | 3 | 2019 | 5323 | 0.030 |
Why?
|
| Ectodysplasins | 1 | 2015 | 12 | 0.030 |
Why?
|
| Flavonoids | 1 | 1999 | 447 | 0.030 |
Why?
|
| Immediate-Early Proteins | 1 | 1998 | 444 | 0.030 |
Why?
|
| Transplantation, Homologous | 2 | 2009 | 4835 | 0.030 |
Why?
|
| Preoperative Period | 1 | 2017 | 565 | 0.030 |
Why?
|
| Cytoskeletal Proteins | 1 | 2001 | 1328 | 0.030 |
Why?
|
| Sex Factors | 1 | 2009 | 10633 | 0.030 |
Why?
|
| Case-Control Studies | 3 | 2020 | 22296 | 0.030 |
Why?
|
| Hospitalization | 1 | 2015 | 10847 | 0.030 |
Why?
|
| Gadolinium | 1 | 2020 | 965 | 0.030 |
Why?
|
| Molecular Sequence Data | 5 | 2007 | 17629 | 0.030 |
Why?
|
| Hepatitis B virus | 2 | 2016 | 533 | 0.030 |
Why?
|
| Interferon-beta | 1 | 1997 | 349 | 0.030 |
Why?
|
| Obesity | 1 | 1997 | 13091 | 0.030 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 2004 | 2848 | 0.030 |
Why?
|
| Disseminated Intravascular Coagulation | 1 | 1995 | 187 | 0.030 |
Why?
|
| Transgenes | 1 | 1998 | 1016 | 0.030 |
Why?
|
| Frozen Sections | 1 | 2015 | 154 | 0.030 |
Why?
|
| National Institutes of Health (U.S.) | 1 | 2018 | 794 | 0.030 |
Why?
|
| Nucleic Acid Hybridization | 2 | 2006 | 1305 | 0.030 |
Why?
|
| Kidney Neoplasms | 1 | 2011 | 4300 | 0.030 |
Why?
|
| Hyperplasia | 1 | 1997 | 1154 | 0.030 |
Why?
|
| Intraoperative Period | 1 | 2015 | 513 | 0.030 |
Why?
|
| Tissue Fixation | 1 | 2015 | 245 | 0.030 |
Why?
|
| Cell Adhesion | 1 | 2001 | 3102 | 0.030 |
Why?
|
| K562 Cells | 1 | 2016 | 648 | 0.030 |
Why?
|
| Liver Neoplasms | 2 | 2008 | 4363 | 0.030 |
Why?
|
| Cytarabine | 1 | 1996 | 697 | 0.030 |
Why?
|
| Equipment Failure Analysis | 1 | 2016 | 848 | 0.030 |
Why?
|
| RNA | 1 | 2024 | 2727 | 0.030 |
Why?
|
| In Situ Nick-End Labeling | 1 | 2015 | 612 | 0.030 |
Why?
|
| Perfusion | 1 | 2019 | 1402 | 0.030 |
Why?
|
| Prodrugs | 1 | 1996 | 275 | 0.030 |
Why?
|
| Data Collection | 1 | 2023 | 3324 | 0.030 |
Why?
|
| Membrane Proteins | 3 | 2011 | 7885 | 0.030 |
Why?
|
| Cytochrome P-450 Enzyme System | 2 | 2007 | 423 | 0.030 |
Why?
|
| Depressive Disorder | 1 | 2006 | 3723 | 0.030 |
Why?
|
| HLA Antigens | 1 | 1999 | 1336 | 0.030 |
Why?
|
| Selection Bias | 1 | 2015 | 360 | 0.030 |
Why?
|
| Transduction, Genetic | 1 | 1996 | 902 | 0.030 |
Why?
|
| Entorhinal Cortex | 1 | 2015 | 288 | 0.030 |
Why?
|
| Cerebellar Ataxia | 1 | 1994 | 151 | 0.030 |
Why?
|
| Age of Onset | 1 | 2020 | 3346 | 0.030 |
Why?
|
| Gene Frequency | 1 | 2020 | 3626 | 0.030 |
Why?
|
| Porphyrins | 1 | 2015 | 352 | 0.030 |
Why?
|
| Testosterone | 1 | 2024 | 2493 | 0.030 |
Why?
|
| Sensitivity and Specificity | 1 | 2008 | 14752 | 0.030 |
Why?
|
| Postoperative Complications | 3 | 2013 | 15889 | 0.030 |
Why?
|
| Vaccines, Synthetic | 1 | 1995 | 622 | 0.030 |
Why?
|
| Infusions, Intravenous | 3 | 2005 | 2231 | 0.030 |
Why?
|
| Immune Tolerance | 1 | 2022 | 2323 | 0.030 |
Why?
|
| Glucagon-Secreting Cells | 1 | 2013 | 42 | 0.030 |
Why?
|
| Drug Resistance | 1 | 2018 | 1599 | 0.030 |
Why?
|
| Valine | 1 | 2014 | 410 | 0.030 |
Why?
|
| Angiogenic Proteins | 1 | 2013 | 101 | 0.030 |
Why?
|
| Radionuclide Imaging | 4 | 2001 | 1998 | 0.030 |
Why?
|
| Benzene Derivatives | 1 | 2012 | 51 | 0.030 |
Why?
|
| Severity of Illness Index | 3 | 2024 | 15951 | 0.030 |
Why?
|
| Qualitative Research | 1 | 2023 | 3143 | 0.020 |
Why?
|
| Interdisciplinary Communication | 1 | 2018 | 937 | 0.020 |
Why?
|
| False Negative Reactions | 1 | 1993 | 575 | 0.020 |
Why?
|
| Rats, Zucker | 2 | 2001 | 131 | 0.020 |
Why?
|
| Coronary Artery Disease | 2 | 2001 | 6569 | 0.020 |
Why?
|
| Absorbable Implants | 1 | 2014 | 338 | 0.020 |
Why?
|
| Encephalomyelitis | 1 | 1991 | 37 | 0.020 |
Why?
|
| Cell Survival | 2 | 2018 | 5793 | 0.020 |
Why?
|
| Class I Phosphatidylinositol 3-Kinases | 1 | 2016 | 906 | 0.020 |
Why?
|
| Cross-Linking Reagents | 1 | 1994 | 692 | 0.020 |
Why?
|
| Longitudinal Studies | 3 | 2019 | 14794 | 0.020 |
Why?
|
| Hematinics | 1 | 2014 | 282 | 0.020 |
Why?
|
| Pneumonia, Pneumocystis | 1 | 1993 | 242 | 0.020 |
Why?
|
| Infarction, Middle Cerebral Artery | 1 | 2015 | 487 | 0.020 |
Why?
|
| Infant | 4 | 2015 | 36556 | 0.020 |
Why?
|
| Prenylation | 1 | 2011 | 37 | 0.020 |
Why?
|
| Indazoles | 1 | 2013 | 306 | 0.020 |
Why?
|
| Arteriovenous Malformations | 1 | 1994 | 396 | 0.020 |
Why?
|
| Drug Combinations | 1 | 1997 | 2089 | 0.020 |
Why?
|
| Epithelioid Cells | 1 | 2011 | 60 | 0.020 |
Why?
|
| Hypoglycemic Agents | 1 | 2023 | 3110 | 0.020 |
Why?
|
| Spinal Puncture | 1 | 1993 | 286 | 0.020 |
Why?
|
| Mice, Inbred BALB C | 2 | 2010 | 6232 | 0.020 |
Why?
|
| Transplantation, Autologous | 1 | 2016 | 2126 | 0.020 |
Why?
|
| Frontal Lobe | 2 | 2014 | 1426 | 0.020 |
Why?
|
| Cooperative Behavior | 1 | 2018 | 1515 | 0.020 |
Why?
|
| Pancreatic Neoplasms | 1 | 2008 | 5443 | 0.020 |
Why?
|
| Hypertrophy | 1 | 2012 | 562 | 0.020 |
Why?
|
| ROC Curve | 1 | 2018 | 3629 | 0.020 |
Why?
|
| Hydroxyurea | 1 | 2011 | 284 | 0.020 |
Why?
|
| Coronary Vessels | 1 | 2001 | 3124 | 0.020 |
Why?
|
| Proteomics | 1 | 2024 | 3914 | 0.020 |
Why?
|
| Adenine | 1 | 2016 | 995 | 0.020 |
Why?
|
| Vena Cava Filters | 1 | 1993 | 270 | 0.020 |
Why?
|
| Epigenesis, Genetic | 1 | 2023 | 3836 | 0.020 |
Why?
|
| Radiation, Ionizing | 1 | 2011 | 252 | 0.020 |
Why?
|
| Kidney Glomerulus | 1 | 2012 | 569 | 0.020 |
Why?
|
| Recombinant Proteins | 3 | 2012 | 6512 | 0.020 |
Why?
|
| Fever | 1 | 2017 | 1619 | 0.020 |
Why?
|
| Inflammation | 1 | 2010 | 10868 | 0.020 |
Why?
|
| Cerebrospinal Fluid | 1 | 1993 | 545 | 0.020 |
Why?
|
| Stroke | 1 | 2012 | 9756 | 0.020 |
Why?
|
| Quality Assurance, Health Care | 1 | 2000 | 2182 | 0.020 |
Why?
|
| Medical Records | 2 | 2010 | 1411 | 0.020 |
Why?
|
| Dietary Fats | 1 | 1997 | 2002 | 0.020 |
Why?
|
| Organ Specificity | 1 | 1994 | 1970 | 0.020 |
Why?
|
| Immunity | 1 | 2015 | 1003 | 0.020 |
Why?
|
| Receptors, Antigen, T-Cell | 1 | 2018 | 2574 | 0.020 |
Why?
|
| Culture Media, Serum-Free | 1 | 2009 | 148 | 0.020 |
Why?
|
| Genes, Bacterial | 2 | 1992 | 1076 | 0.020 |
Why?
|
| Angiogenesis Inducing Agents | 1 | 2011 | 255 | 0.020 |
Why?
|
| Ultraviolet Rays | 1 | 1994 | 1104 | 0.020 |
Why?
|
| Antibodies, Monoclonal, Murine-Derived | 1 | 2012 | 696 | 0.020 |
Why?
|
| Forecasting | 2 | 1999 | 2945 | 0.020 |
Why?
|
| Insulin | 1 | 2023 | 6610 | 0.020 |
Why?
|
| Bromodeoxyuridine | 1 | 2009 | 310 | 0.020 |
Why?
|
| Autonomic Nervous System | 1 | 2014 | 709 | 0.020 |
Why?
|
| Tubulin Modulators | 1 | 2009 | 106 | 0.020 |
Why?
|
| HeLa Cells | 2 | 2011 | 3076 | 0.020 |
Why?
|
| Immunologic Memory | 1 | 2015 | 1378 | 0.020 |
Why?
|
| Injections | 1 | 1992 | 841 | 0.020 |
Why?
|
| Porosity | 1 | 2009 | 352 | 0.020 |
Why?
|
| Hydrolysis | 1 | 2009 | 646 | 0.020 |
Why?
|
| CpG Islands | 1 | 2013 | 1210 | 0.020 |
Why?
|
| Glutamic Acid | 1 | 2014 | 1191 | 0.020 |
Why?
|
| Microcirculation | 1 | 2013 | 1281 | 0.020 |
Why?
|
| Crystallization | 1 | 2009 | 520 | 0.020 |
Why?
|
| Germ-Line Mutation | 1 | 2017 | 1887 | 0.020 |
Why?
|
| Infant, Newborn | 3 | 2015 | 26428 | 0.020 |
Why?
|
| Equipment Design | 1 | 2016 | 3530 | 0.020 |
Why?
|
| Cell Division | 4 | 1998 | 4478 | 0.020 |
Why?
|
| Cystic Fibrosis | 1 | 1997 | 1295 | 0.020 |
Why?
|
| Carrier Proteins | 2 | 2000 | 4939 | 0.020 |
Why?
|
| ATP-Binding Cassette Transporters | 1 | 2011 | 567 | 0.020 |
Why?
|
| Cell Movement | 2 | 2008 | 5216 | 0.020 |
Why?
|
| Adenoviridae | 3 | 1997 | 1095 | 0.020 |
Why?
|
| Computational Biology | 1 | 2020 | 3562 | 0.020 |
Why?
|
| Polyneuropathies | 1 | 2009 | 139 | 0.020 |
Why?
|
| Blood Volume | 1 | 2009 | 546 | 0.020 |
Why?
|
| Rabbits | 2 | 2009 | 4774 | 0.020 |
Why?
|
| Cells, Cultured | 2 | 2016 | 19023 | 0.020 |
Why?
|
| Encephalitis | 1 | 1991 | 441 | 0.020 |
Why?
|
| Fluorodeoxyglucose F18 | 1 | 2016 | 2056 | 0.020 |
Why?
|
| Cytochrome P-450 CYP3A | 1 | 2007 | 118 | 0.020 |
Why?
|
| Flow Cytometry | 2 | 2009 | 5906 | 0.020 |
Why?
|
| Anaplasia | 1 | 2007 | 16 | 0.020 |
Why?
|
| Metabolic Clearance Rate | 1 | 2007 | 363 | 0.020 |
Why?
|
| Transcriptional Activation | 1 | 1993 | 1750 | 0.020 |
Why?
|
| Toll-Like Receptor 9 | 1 | 2008 | 199 | 0.020 |
Why?
|
| Epidermal Growth Factor | 1 | 2010 | 697 | 0.020 |
Why?
|
| Culture Media | 1 | 2009 | 898 | 0.020 |
Why?
|
| Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 1 | 1992 | 686 | 0.020 |
Why?
|
| Skin | 2 | 2018 | 4506 | 0.020 |
Why?
|
| DNA-Binding Proteins | 3 | 2000 | 9618 | 0.020 |
Why?
|
| Electrophoresis, Gel, Two-Dimensional | 1 | 2007 | 283 | 0.020 |
Why?
|
| Apoptosis | 2 | 2015 | 9527 | 0.020 |
Why?
|
| Gene Silencing | 1 | 2013 | 1505 | 0.020 |
Why?
|
| Leukemia, Lymphocytic, Chronic, B-Cell | 1 | 2018 | 1642 | 0.020 |
Why?
|
| Intracranial Arteriovenous Malformations | 1 | 1990 | 366 | 0.020 |
Why?
|
| Early Diagnosis | 1 | 2011 | 1194 | 0.020 |
Why?
|
| Gene Expression Regulation, Developmental | 1 | 1998 | 3612 | 0.020 |
Why?
|
| Secondary Prevention | 1 | 2013 | 1476 | 0.020 |
Why?
|
| Biopsy | 2 | 1995 | 6805 | 0.020 |
Why?
|
| Islets of Langerhans | 1 | 2013 | 1351 | 0.020 |
Why?
|
| Surface Properties | 1 | 2009 | 1169 | 0.020 |
Why?
|
| Sacrum | 1 | 2008 | 275 | 0.020 |
Why?
|
| NF-kappa B | 1 | 2015 | 2492 | 0.020 |
Why?
|
| Injections, Intralesional | 2 | 1998 | 280 | 0.020 |
Why?
|
| Actuarial Analysis | 2 | 1999 | 372 | 0.020 |
Why?
|
| Materials Testing | 1 | 2009 | 873 | 0.020 |
Why?
|
| Neoplasm Proteins | 1 | 1998 | 3608 | 0.020 |
Why?
|
| Adenosine Triphosphate | 1 | 2012 | 2003 | 0.020 |
Why?
|
| Protease Inhibitors | 1 | 2009 | 752 | 0.020 |
Why?
|
| Insulin-Secreting Cells | 1 | 2013 | 899 | 0.020 |
Why?
|
| ras Proteins | 1 | 2011 | 1058 | 0.020 |
Why?
|
| Particle Size | 1 | 2009 | 1652 | 0.020 |
Why?
|
| Gene Knockdown Techniques | 1 | 2009 | 1608 | 0.020 |
Why?
|
| Chemokines, CXC | 1 | 2007 | 420 | 0.020 |
Why?
|
| Lymphocyte Activation | 1 | 2016 | 5505 | 0.010 |
Why?
|
| Chemokine CXCL12 | 1 | 2007 | 457 | 0.010 |
Why?
|
| Enkephalin, Leucine-2-Alanine | 1 | 1984 | 9 | 0.010 |
Why?
|
| Enkephalin, Leucine | 1 | 1984 | 16 | 0.010 |
Why?
|
| Binding Sites | 3 | 2000 | 6023 | 0.010 |
Why?
|
| Imaging, Three-Dimensional | 1 | 2018 | 4076 | 0.010 |
Why?
|
| Antihypertensive Agents | 1 | 2014 | 2027 | 0.010 |
Why?
|
| beta-Endorphin | 1 | 1984 | 43 | 0.010 |
Why?
|
| RNA, Neoplasm | 1 | 2007 | 751 | 0.010 |
Why?
|
| Skin Neoplasms | 2 | 1995 | 5864 | 0.010 |
Why?
|
| Retroviridae | 2 | 1997 | 849 | 0.010 |
Why?
|
| Protein Transport | 1 | 2009 | 1956 | 0.010 |
Why?
|
| Leukocytes | 1 | 1992 | 2034 | 0.010 |
Why?
|
| Chi-Square Distribution | 1 | 2010 | 3438 | 0.010 |
Why?
|
| Radiographic Image Enhancement | 1 | 2008 | 877 | 0.010 |
Why?
|
| HIV Infections | 1 | 2010 | 17591 | 0.010 |
Why?
|
| Plasmids | 3 | 1995 | 2269 | 0.010 |
Why?
|
| Spinal Cord | 2 | 2005 | 1813 | 0.010 |
Why?
|
| Vaccination | 1 | 2016 | 3438 | 0.010 |
Why?
|
| Autoradiography | 2 | 1997 | 728 | 0.010 |
Why?
|
| Laryngeal Neoplasms | 1 | 2007 | 514 | 0.010 |
Why?
|
| HIV | 1 | 2010 | 1597 | 0.010 |
Why?
|
| Cost-Benefit Analysis | 1 | 2016 | 5544 | 0.010 |
Why?
|
| DNA Primers | 1 | 2007 | 2827 | 0.010 |
Why?
|
| Medicare | 1 | 2021 | 6888 | 0.010 |
Why?
|
| Immunologic Factors | 1 | 2011 | 1597 | 0.010 |
Why?
|
| Cholesterol | 1 | 2011 | 2913 | 0.010 |
Why?
|
| Neurologic Examination | 1 | 2005 | 916 | 0.010 |
Why?
|
| Fatty Acids | 1 | 2009 | 1812 | 0.010 |
Why?
|
| Heart Defects, Congenital | 1 | 2018 | 4712 | 0.010 |
Why?
|
| Cell Line | 4 | 2001 | 15604 | 0.010 |
Why?
|
| Monocytes | 1 | 2011 | 2603 | 0.010 |
Why?
|
| Cloning, Molecular | 2 | 1998 | 4168 | 0.010 |
Why?
|
| Transplantation Conditioning | 1 | 2008 | 1601 | 0.010 |
Why?
|
| Hepatocyte Nuclear Factor 1 | 1 | 2000 | 27 | 0.010 |
Why?
|
| Escherichia coli | 2 | 1992 | 4213 | 0.010 |
Why?
|
| Collagen | 1 | 2009 | 2646 | 0.010 |
Why?
|
| Fibroblast Growth Factors | 1 | 2007 | 873 | 0.010 |
Why?
|
| Hepatocyte Nuclear Factor 1-beta | 1 | 2000 | 93 | 0.010 |
Why?
|
| Genes, p16 | 1 | 2000 | 159 | 0.010 |
Why?
|
| Regression Analysis | 1 | 2010 | 6346 | 0.010 |
Why?
|
| Immunotherapy, Adoptive | 1 | 2010 | 1520 | 0.010 |
Why?
|
| Genes, erbB-1 | 1 | 2000 | 163 | 0.010 |
Why?
|
| High Mobility Group Proteins | 1 | 2000 | 179 | 0.010 |
Why?
|
| Protein Precursors | 1 | 1984 | 1135 | 0.010 |
Why?
|
| Glucocorticoids | 1 | 2009 | 2167 | 0.010 |
Why?
|
| Exons | 1 | 2005 | 2395 | 0.010 |
Why?
|
| Epimedium | 1 | 1999 | 2 | 0.010 |
Why?
|
| Neurons | 1 | 2019 | 9519 | 0.010 |
Why?
|
| CCAAT-Enhancer-Binding Proteins | 1 | 2000 | 288 | 0.010 |
Why?
|
| Membrane Fluidity | 1 | 1999 | 67 | 0.010 |
Why?
|
| Erythema Multiforme | 1 | 1999 | 31 | 0.010 |
Why?
|
| HMGB1 Protein | 1 | 2000 | 141 | 0.010 |
Why?
|
| Radiodermatitis | 1 | 1999 | 61 | 0.010 |
Why?
|
| Glycerolphosphate Dehydrogenase | 1 | 1998 | 40 | 0.010 |
Why?
|
| Chromosome Mapping | 1 | 2007 | 4625 | 0.010 |
Why?
|
| Phenytoin | 1 | 1999 | 189 | 0.010 |
Why?
|
| Hypercholesterolemia | 1 | 2005 | 1145 | 0.010 |
Why?
|
| Analysis of Variance | 2 | 1999 | 6236 | 0.010 |
Why?
|
| Early Growth Response Protein 1 | 1 | 1998 | 133 | 0.010 |
Why?
|
| Genes, p53 | 1 | 2000 | 716 | 0.010 |
Why?
|
| Plants, Medicinal | 1 | 1999 | 167 | 0.010 |
Why?
|
| Carcinoma, Embryonal | 1 | 1998 | 36 | 0.010 |
Why?
|
| Bronchial Arteries | 1 | 1997 | 21 | 0.010 |
Why?
|
| Health Surveys | 1 | 2008 | 4055 | 0.010 |
Why?
|
| Animal Nutritional Physiological Phenomena | 1 | 1997 | 54 | 0.010 |
Why?
|
| Immunity, Innate | 1 | 2010 | 3080 | 0.010 |
Why?
|
| Retinoblastoma-Binding Protein 1 | 1 | 1997 | 138 | 0.010 |
Why?
|
| Transcription Factor DP1 | 1 | 1997 | 136 | 0.010 |
Why?
|
| Inguinal Canal | 1 | 1997 | 71 | 0.010 |
Why?
|
| Genome | 1 | 2005 | 1754 | 0.010 |
Why?
|
| E2F1 Transcription Factor | 1 | 1997 | 182 | 0.010 |
Why?
|
| Transcription, Genetic | 3 | 1997 | 7609 | 0.010 |
Why?
|
| Conserved Sequence | 1 | 2000 | 1162 | 0.010 |
Why?
|
| Retroperitoneal Space | 1 | 1997 | 173 | 0.010 |
Why?
|
| E2F Transcription Factors | 1 | 1997 | 270 | 0.010 |
Why?
|
| Blood Glucose | 2 | 2001 | 6435 | 0.010 |
Why?
|
| Presenilin-1 | 1 | 2001 | 665 | 0.010 |
Why?
|
| 3T3 Cells | 1 | 1998 | 1085 | 0.010 |
Why?
|
| Transplantation Tolerance | 1 | 2001 | 633 | 0.010 |
Why?
|
| T-Lymphocytes, Regulatory | 1 | 2010 | 3116 | 0.010 |
Why?
|
| Reoperation | 2 | 1999 | 4342 | 0.010 |
Why?
|
| Cytoplasm | 1 | 2001 | 1505 | 0.010 |
Why?
|
| Sarcoma, Experimental | 1 | 1996 | 117 | 0.010 |
Why?
|
| Technetium Tc 99m Exametazime | 1 | 1996 | 61 | 0.010 |
Why?
|
| Leukemia, Myeloid, Acute | 1 | 1992 | 3626 | 0.010 |
Why?
|
| Injections, Spinal | 1 | 1997 | 318 | 0.010 |
Why?
|
| Cytosine Deaminase | 1 | 1996 | 65 | 0.010 |
Why?
|
| Cytoskeleton | 1 | 2001 | 1179 | 0.010 |
Why?
|
| beta Catenin | 1 | 2001 | 1047 | 0.010 |
Why?
|
| Epididymis | 1 | 1997 | 227 | 0.010 |
Why?
|
| Anemia | 1 | 2005 | 1517 | 0.010 |
Why?
|
| Paralysis | 1 | 1997 | 250 | 0.010 |
Why?
|
| Diabetes Complications | 1 | 2001 | 1320 | 0.010 |
Why?
|
| Leukocytes, Mononuclear | 1 | 2001 | 1855 | 0.010 |
Why?
|
| Cell Line, Transformed | 1 | 1996 | 867 | 0.010 |
Why?
|
| Altitude | 1 | 1995 | 163 | 0.010 |
Why?
|
| Glycosylation | 1 | 1997 | 1101 | 0.010 |
Why?
|
| Logistic Models | 2 | 1999 | 13318 | 0.010 |
Why?
|
| Linear Models | 1 | 2004 | 5891 | 0.010 |
Why?
|
| Bronchi | 1 | 1997 | 850 | 0.010 |
Why?
|
| Binding Sites, Antibody | 1 | 1994 | 340 | 0.010 |
Why?
|
| Sequence Homology, Amino Acid | 1 | 1998 | 2749 | 0.010 |
Why?
|
| Viral Regulatory and Accessory Proteins | 1 | 1993 | 150 | 0.010 |
Why?
|
| Proto-Oncogene Proteins c-raf | 1 | 1993 | 205 | 0.010 |
Why?
|
| Restriction Mapping | 1 | 1993 | 849 | 0.010 |
Why?
|
| Cross-Sectional Studies | 1 | 2014 | 26395 | 0.010 |
Why?
|
| Cerebellopontine Angle | 1 | 1993 | 53 | 0.010 |
Why?
|
| Proto-Oncogene Proteins c-jun | 1 | 1993 | 287 | 0.010 |
Why?
|
| Neural Conduction | 1 | 1994 | 443 | 0.010 |
Why?
|
| Cell Adhesion Molecules, Neuronal | 1 | 1994 | 263 | 0.010 |
Why?
|
| Immunity, Cellular | 1 | 1998 | 1560 | 0.010 |
Why?
|
| Hypnotics and Sedatives | 1 | 2000 | 1191 | 0.010 |
Why?
|
| Antigens, Differentiation, T-Lymphocyte | 1 | 1994 | 896 | 0.010 |
Why?
|
| Macaca fascicularis | 1 | 1994 | 913 | 0.010 |
Why?
|
| Peptide Fragments | 1 | 1984 | 5151 | 0.010 |
Why?
|
| Vitamin E | 1 | 1995 | 874 | 0.010 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2007 | 4064 | 0.010 |
Why?
|
| Aorta, Thoracic | 1 | 1997 | 1112 | 0.010 |
Why?
|
| Genes, Reporter | 1 | 1995 | 1524 | 0.010 |
Why?
|
| Kinetics | 1 | 1998 | 6332 | 0.010 |
Why?
|
| Tomography, Emission-Computed, Single-Photon | 1 | 1996 | 1141 | 0.010 |
Why?
|
| Lipids | 1 | 2001 | 3345 | 0.010 |
Why?
|
| Acute Disease | 2 | 1991 | 7245 | 0.010 |
Why?
|
| Genetic Engineering | 1 | 1995 | 936 | 0.010 |
Why?
|
| Hemiplegia | 1 | 1990 | 137 | 0.010 |
Why?
|
| Particle Accelerators | 1 | 1990 | 173 | 0.010 |
Why?
|
| Cell Membrane | 1 | 1999 | 3659 | 0.010 |
Why?
|
| Epithelial Cells | 1 | 2001 | 3702 | 0.000 |
Why?
|
| Protein Kinase C | 1 | 1993 | 1207 | 0.000 |
Why?
|
| Transplantation, Heterologous | 1 | 1997 | 2395 | 0.000 |
Why?
|
| Electromyography | 1 | 1994 | 1401 | 0.000 |
Why?
|
| Aphasia | 1 | 1990 | 193 | 0.000 |
Why?
|
| Virus Replication | 1 | 1996 | 2458 | 0.000 |
Why?
|
| Pain Measurement | 1 | 1998 | 3586 | 0.000 |
Why?
|
| Gonadal Steroid Hormones | 1 | 1992 | 708 | 0.000 |
Why?
|
| Antioxidants | 1 | 1995 | 1673 | 0.000 |
Why?
|
| Patient Care Team | 1 | 1999 | 2528 | 0.000 |
Why?
|
| Body Weight | 1 | 1997 | 4628 | 0.000 |
Why?
|
| Vomiting | 1 | 1990 | 655 | 0.000 |
Why?
|
| RNA, Messenger | 1 | 2001 | 12806 | 0.000 |
Why?
|
| Erythrocytes | 1 | 1995 | 2421 | 0.000 |
Why?
|
| Amino Acid Sequence | 1 | 1998 | 13427 | 0.000 |
Why?
|
| Alopecia | 1 | 1990 | 416 | 0.000 |
Why?
|
| Cerebrovascular Circulation | 1 | 1996 | 2734 | 0.000 |
Why?
|
| Functional Laterality | 1 | 1992 | 2267 | 0.000 |
Why?
|
| Carcinoma, Hepatocellular | 1 | 1998 | 2336 | 0.000 |
Why?
|
| Radiology | 1 | 1999 | 2104 | 0.000 |
Why?
|
| Heart | 1 | 1997 | 4447 | 0.000 |
Why?
|
| Antigens, CD | 1 | 1994 | 4032 | 0.000 |
Why?
|
| Immunoglobulin G | 1 | 1994 | 4568 | 0.000 |
Why?
|
| Prenatal Exposure Delayed Effects | 1 | 1992 | 2542 | 0.000 |
Why?
|
| Carcinoma | 1 | 1990 | 2340 | 0.000 |
Why?
|
| Pregnancy | 1 | 1992 | 30265 | 0.000 |
Why?
|